


Review

Advances in the Immunomodulatory Properties of Glycoantigens in Cancer

Valeria da Costa and Teresa Freire * 

Laboratorio de Inmunomodulación y Desarrollo de Vacunas, Departamento de Inmunobiología, Facultad de Medicina, Universidad de La República, Montevideo 11800, Uruguay; valedacosta21@gmail.com
* Correspondence: tfreire@fmed.edu.uy; Tel.: +598-2924-9562; Fax: +598-2924-9563

Simple Summary: This work reviews the role of aberrant glycosylation in cancer cells during tumour growth and spreading, as well as in immune evasion. The interaction of tumour-associated glycans with the immune system through C-type lectin receptors can favour immune escape but can also provide opportunities to develop novel tumour immunotherapy strategies. This work highlights the main findings in this area and spotlights the challenges that remain to be investigated.

Abstract: Aberrant glycosylation in tumour progression is currently a topic of main interest. Tumour-associated carbohydrate antigens (TACAs) are expressed in a wide variety of epithelial cancers, being both a diagnostic tool and a potential treatment target, as they have impact on patient outcome and disease progression. Glycans affect both tumour-cell biology properties as well as the antitumour immune response. It has been ascertained that TACAs affect cell migration, invasion and metastatic properties both when expressed by cancer cells or by their extracellular vesicles. On the other hand, tumour-associated glycans recognized by C-type lectin receptors in immune cells possess immunomodulatory properties which enable tumour growth and immune response evasion. Yet, much remains unknown, concerning mechanisms involved in deregulation of glycan synthesis and how this affects cell biology on a major level. This review summarises the main findings to date concerning how aberrant glycans influence tumour growth and immunity, their application in cancer treatment and spotlights of unanswered challenges remaining to be solved.

Keywords: glycans; cancer; tumour-associated carbohydrate antigens; C-type lectin receptors; immunomodulation; metastasis



Citation: da Costa, V.; Freire, T. Advances in the Immunomodulatory Properties of Glycoantigens in Cancer. *Cancers* **2022**, *14*, 1854. <https://doi.org/10.3390/cancers14081854>

Academic Editor: Nikos Karamanos

Received: 13 February 2022

Accepted: 28 March 2022

Published: 7 April 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Tumour-Associated Carbohydrate Antigens

Glycosylation is a highly regulated and complex posttranslational modification that is of great importance in the modulation of the activities and functions of glycoproteins in biological systems. The mammalian glycome repertoire is estimated to be between hundreds and thousands of glycan motifs, with a vast diversity of glycan structures [1]. These are a result of different linkages and carbohydrate moieties that combine to generate different structures, which encode various types of information and allow them to participate in a great number of cellular processes, such as cell proliferation, adhesion, and migration. These effects are mediated by the glycan charge, bulkiness, and hydrophilicity, as well as the capacity of transmitting information by interacting with specific lectin or lectin-like receptors [2].

Fundamental changes in the glycosylation patterns of cell surface and secreted glycoproteins occur during malignant transformation and cancer progression [1,3]. Changes in glycosylation induce the appearance of unmasked glycan antigens in the surface of tumour cells, known as tumour-associated carbohydrate antigens (TACAs) [3–6]. There is a vast amount of documented evidence that changes in glycosylation are a hallmark of cancer and their role in tumour development has been extensively studied [3,6].

Aberrant protein glycosylation in cancer includes both changes in *N*-glycosylation and *O*-glycosylation. The expression of cancer-associated glycans, such as sialyl-Lewis^x (sLe^x), Thomsen-nouvelle antigen (Tn), and sialyl-Tn (sTn) antigens has been detected in almost every human carcinoma cancer type [7]. The glycan structures of these glycoantigens are depicted in Figure 1.




Figure 1. Tumour-associated glycoantigens expressed in adenocarcinoma cells. TACAs present in *O*-glycoproteins (yellow background), *N*-glycoproteins (blue background), GAGs (purple background) and glycolipids (green background) are shown. Their usual names are written in red.

In this review we will first focus on the different glycans structures found in tumours, the biological effect of aberrant glycosylation in tumour cells and how glycans may modulate cancer immunity by interacting with specific receptors found in immune cells.

1.1. *N*-glycan Branching

N-glycosylation is characterised by the addition of a precursor glycan structure onto the side chains of Asn (within the consensus sequence Asn-X-Ser/Thr), which is then decorated by the action of both glycosidases and glycosyltransferases [8]. TACAs in *N*-glycans can also comprise increased formation of extensively branched structures [9]. This is mainly catalysed by three glycosyltransferases, which will be described below.

The β 1,4-*N*-acetylglucosaminyltransferase (GnT-III) catalyses the transfer of GlcNAc from UDP-GlcNAc to biantennary sugar chains to produce a β 1,4GlcNAc linkage designated as a bisecting GlcNAc structure [10]. Interestingly, *N*-glycans with a bisecting structure were shown to decrease with the development of malignancy in colorectal cancer [11].

On the other hand, the increased expression of β 1-6 branched *N*-oligosaccharides, catalysed by the golgi enzyme *N*-acetylglucosaminyl transferase-V (GnT-V), is also related to cancer progression and aggressiveness, particularly in the breast, colon, oesophagus gliomas and endometrium [12,13]. The β 1,6-*N*-acetylglucosaminyl transferase (GnT-V) catalyses β 1,6GlcNAc branching, which may later be elongated to a poly-lactosamine and a sLe^x structure on various growth factor receptors such as epidermal growth factor receptor (EGFR), fibroblast growth factor receptors (FGFR) and Insulin Like Growth Factor 1 Receptor (IGFR) on the cell surface [10].

Finally, the α 1,6-fucosyltransferase (FUT8) catalyses the transfer reaction from GDP-Fucose to produce a core fucose moiety [9]. Alterations in its expression have been reported in hepatoma, pancreatic, colon, liver, breast, prostate, thyroid non-small cell lung cancer and melanoma [10].

In a recent proteomic study of *N*-glycosylation in breast cancer tissues, Scott and collaborators detected an increased number of Man8/Man9 glycans in HER2⁺ tissues [14]. This is an indicator of less mannosidase processing during biosynthesis, which leads to proteins that are normally destined for lysosomes to be secreted or transported to the cell surface [14]. In the same study, the authors evidenced that the presence of poly-LacNAc structures (a linear structure comprising the repeating *N*-acetyl-lactosamine unit (Gal β 1-4GlcNAc β 1-3) (see Figure 1) are associated with more aggressive breast cancers [14].

1.2. Mucin Type O-glycans

O-linked glycosylation is characterised by the addition of glycans onto the side chains of Ser or Thr [8] on a one step-manner process that includes the addition of single monosaccharides in sequential order by glycosyltransferases [15]. Several tumour-associated O-glycans have been identified and extensively characterised as key modulating agents of tumour progression. These tumour O-glycans comprise oncofetal antigens (which are rare in normal adult tissue but may be found in embryonic tissues) neoantigens (which are not found neither in adult or in embryonic tissues and therefore conform novel structures), and antigens expressed in altered levels [16]. The most common TACAs formed from incomplete O-glycan synthesis are GalNAc α -O-Ser/Thr (Tn, Thomsen Nouveau, CD175), Neu5Ac α 2,6-GalNAc α -O-Ser/Thr (sTn, sialyl-Tn, CD175s), Gal β 1,3-GalNAc α -O-Ser/Thr (TF, Thomsen-Friedenreich, CD176, also known as T antigen) and Neu5Ac α 2,6- and Neu5Ac α 2,3-Gal β 1,3-GalNAc α -O-Ser/Thr (2,6-sTF, 2,3-sTF, respectively) [17]. In addition, some extended O-glycans may be found in tumour cells, such as the ABO(H) antigens, the Lewis antigens and poly-*N*-acetyl-lactosamine [16] (Figure 1).

Often, mucins, which are large and heavily O-glycosylated proteins, have been associated with aberrant O-glycosylated antigens [17]. In addition, their expression in cancer cells is reported to be associated with a more malignant phenotype. For instance, Mucin-1 (MUC1) expression on tumour cells differ from normal cells, mainly due to an upregulation of gene expression and to O-glycans being truncated, mostly exhibiting core 1 O-glycan structures [17]. Moreover, MUC1 is a prognostic marker for colorectal adenocarcinoma [18], while MUC4, MUC1 and MUC5A are reported as biomarkers for pancreatic cancer [19–21]. In addition, MUC16, which is overexpressed in ovarian cancer and pancreatic cancer cells, enhances cell survival, mainly by protecting them from recognition by cytotoxic cells such as Natural Killer (NK) cells, and enabling their dissemination and development of metastasis in the peritoneal cavity [22]. MUC16 from metastatic pancreatic cells can also bind to E- and L-selectin mediated by sialofucosylated structures in the mucin O- and N-glycans, enhancing their metastatic capacity [23]. Furthermore, MUC4 in breast cancer is associated with circulating tumour cells and with an increase of tumour cell survival in circulation, promoting metastasis [24]. Nevertheless, the expression of mucins may also be associated with a protective phenotype towards malignancy. For instance, MUC2 acts as a protective component of the mucus layer in the colon. Indeed, MUC2 downregulation is associated with tumour progression in colon cancer and metastasis, via the enhancement

of the proinflammatory axis IL-6-gp130-STAT3, that contributes to chronic inflammation and tumorigenesis [25].

1.3. Sialylation

Sialylation is a relevant modification in cellular glycosylation, as sialic acids are known to participate in cell signalling, immune response and cellular interaction [26]. Sialic acids have a negative charge at physiological pH, which affects protein conformation and oligomerization, as well as interaction with other proteins or components of the extracellular matrix [27]. There are twenty Golgi localised sialyltransferases with different substrate and linkage specificity in charge of protein and lipid sialylation [27]. The most common types of sialic acids in mammals are *N*-acetylneuraminic acid (Neu5Ac) and *N*-glycolylneuraminic acid (Neu5Gc), but humans lost the ability to synthesise Neu5Gc due to a gene deletion in the enzyme in charge of sialic acid synthesis [27]. Nevertheless, there still can be found Neu5Gc in human tissues, obtained from diet, such as red meat, and the incorporation of this to glycoproteins and gangliosides has been shown to promote inflammation and tumour progression [28].

Cancer-associated glycans often exhibit an increased amount of sialic acid. Augmented sialylation of tumour cells has been correlated with a metastatic phenotype and poor prognosis in patients with cancer [29]. Both *N*- and *O*-glycans have terminal sialic acid incorporated in their structures. Some relevant sialylated TACAs include the α 2,6-sialylated lactosamine (Sia6LacNAc), synthesised by the β -galactoside α 2,6-sialyltransferase I (ST6Gal-I), an enzyme with altered expression in various types of cancer, such as colon, stomach, and ovarian cancer [30]. Furthermore, the sialylated variants of sLe^a and sLe^x are highly expressed in cancer and correlate with decreased survival [30]. In the same line, the sulphated sLe^a and sLe^x variants and nonfucosylated sialyl-LacNAc type [31] have been associated with particular differentiation states and subgroups of pancreatic cancer cells [32].

1.4. Glycosphingolipids

Lipid glycosylation in the secretory pathway gives place to glycosphingolipids (GSLs), including the glycolipid that anchors glycosylphosphatidylinositol (GPI)-linked proteins [1]. Glycolipids are compounds containing a carbohydrate group linked by glycosyl linkage to a lipid moiety [33]. The basic structure of the GSL is the ceramide, determined by long-chain amino alcohol sphingosine, originated from palmitoyl coenzyme-A and Ser, in amide linkage to a fatty acid. Monosaccharides or oligosaccharides chains are ligated to the ceramide via glycosidic linkage, constituting the basic platform for chain extension to the oligoglycosylceramides [33].

The main changes in cancer progression derive from differences in GSL level expression. Gangliosides such as GM3, GM2, CD3 and GD2 are often found overexpressed in tumours compared to normal tissues, including lung cancer, melanoma, and neuroblastoma [26].

1.5. Glycosaminoglycans

Glycosaminoglycans (GAGs) are also linked to serine and threonine; they are linear, constructed through disaccharide repeats formed by GlcNAc or GalNAc, combined with an uronic acid or galactose, and are produced by different biosynthetic pathways than *N*- and *O*-glycans and are often highly sulfated [1,34]. Glycosaminoglycans are functionally diverse and include heparan sulfate, chondroitin sulfate and dermatan sulfate [35]. The biosynthesis of GAGs begins in the cellular cytoplasm and continues in the Golgi apparatus, where sulfation of functional groups takes place. Then, the sulfated GAGs are linked covalently to anchor proteins called proteoglycans [36]. Of note, hyaluronic acid does not go through sulfation in Golgi apparatus, but the precursor sugar is transported to the cellular membrane for further processing without sulfation [36].

Interestingly, low levels of cell surface heparan sulphate and syndecan-1 correlate with high metastatic activity of many tumours, including colon, mesothelioma, lung, hepatocellular carcinoma, infiltrating ductal carcinoma of the breast, and head and neck

carcinoma [37]. In colorectal cancer, it has been reported that neoplastic tissues have an increased amount of chondroitin sulphate and dermatan sulphate compared to non-neoplastic mucosal tissues, while heparan sulphate was decreased in neoplastic tissues [38]. Furthermore, it has also been observed that the alteration in the expression of heparan sulphate proteoglycans is dependent on the metastatic nature of the tumour [39].

2. TACAs as Mediators of Cancer Progression

The cellular surface exposes a great variety of glycoconjugates, comprising macromolecules containing carbohydrates in their structure. The membrane asymmetry exposes the glycan portion of the proteins to the extracellular space, forming, therefore, the glycocalyx [40,41]. This lightens, as already expressed, the importance of glycans in the normal cellular processes, such as cell–cell communication, interaction with the extracellular matrix and soluble factors. Both the glycans in the surface proteins and the ones expressed in soluble proteins play a fundamental role in modulating and mediating several key events in the development and progression of cancer [42]. Furthermore, some works demonstrate their role as potential biodiagnostic markers of cancer, to follow up patient prognosis and to develop antitumor immunotherapy strategies [43,44]. To illustrate some examples, detecting a glycan signature in serum prostate specific antigen (PSA) increases the sensitivity of this approach as a diagnostic tool for pancreatic cancer [45]. Furthermore, the detection of α -2,3-sialic acid in PSA enhances sensitivity to differentiate high-risk malignant cancer from benign disease [46]. Serum sialyl-sTn levels are also reported to be associated with histological grade and lymph node metastasis in endometrial cancer [47]. Moreover, a study showed that sialyltransferase levels in plasma of cancer patients are elevated [48].

2.1. Cellular Proliferation and Survival

Glycans may stabilise the expression of cellular receptors on the cell surface and therefore modulate the interaction between the receptor and its ligand, and its downstream signalling. For instance, the role of *N*-glycans is crucial in checkpoint signalling mediated by the programmed death-1 (PD1) and PD1 ligand (PD-L1). PD-L1 is reported to be glycosylated in various types of cancer, including melanoma, breast, lung, and colon [49]. In triple negative breast cancer, the downregulation of the β -1,3-*N*-acetylglucosaminyl transferase (B3GNT3) enhances T cell mediated anti-tumour immunity mediated by PD-L1 and PD1 interaction [50]. Furthermore, *N*-glycans may also modulate growth factors receptors signalling, including EGFR, platelet-derived growth factor (PDGF), hepatocyte growth factor receptor (HGFR), FGFR, and IGFR [51], mainly due to the high number of *N*-glycan sites in growth factors. The receptors bind to each other, forming a grid making them resistant to endocytosis, which enhances active signalling that leads to cell growth and proliferation in cancer [10]. In addition, high mannosylated glycoforms are expressed in EGFR, comprising a strong tumour marker [52].

Furthermore, ceramide glycosylation in glycosphingolipids participate in the cell signalling through the proto-oncogene tyrosine-protein kinase Src/ β -catenin pathway and participate in the maintenance of pluripotency in undifferentiated embryonic stem cells [53]. This property has been exploited by breast cancer stem cells, in which glycosylation and globotriaosylceramide (Gb3) expression enhancement correlate with the number of these cells. Silencing the enzyme responsible for the synthesis of this glycan moiety, the glucosylceramide synthase, results in the death of the breast cancer stem cells through the deactivation of c-Src/ β -catenin signalling [53].

Proteoglycans are also involved in cell signalling. Particularly, Syndecan 1, a cell surface heparan sulphate proteoglycan, acts as a coreceptor for a multitude of biological factors such as growth factors, angiogenic factors, cytokines, and chemokines [54]. In cancer, the dysregulated expression of Syndecan 1 alters cell proliferation and invasion [54].

In some cases, aberrant glycosylation may potentiate intrinsic protein malignant features. *O*-glycosylated MUC4, a glycoprotein overexpressed in pancreatic ductal adenocarcinoma (PDAC), potentiates malignancy properties in cancer cells [55]. Interestingly, it has

been seen that glycosylation enhances MUC4 malignant properties through the interaction with epidermal growth factor receptors, and reduces sensitivity to gemcitabine, via altering ErbB/AKT signalling cascades and expression of nucleoside transporters [55]. Finally, hypersialylation of tumour cell surfaces also enhances cancer resistance to chemotherapy [27].

2.2. Adhesion, Migration and Metastasis

Glycans participate in cellular adhesion and allow the reorganisation of the cell surface to expose proteins essential for cellular communication and interaction. For instance, mucins interact with cell-adhesion molecules, and can block cell–cell adhesion mediated by E-cadherin and integrins. E-cadherin, a transmembrane glycoprotein, is the main epithelial cell–cell adhesion molecule, and loss of its expression or mislocalization to cytoplasm is related to the epithelial-to-mesenchymal transition (EMT), wound healing, cancer progression, and metastasis [56,57]. Particularly, O-GalNAc glycosylation of E-cadherin mediated by GalNAc-transferase 3 (GALNT3) correlates with the localization of E-cadherin, and when GALNT3 expression is lost, E-cadherin is retained in the Golgi apparatus, which disrupts adhesion junctions and induces EMT [58]. Selectins are glycan binding proteins that bind TACAs present in the surface of glycoproteins or in the extracellular matrix of cancer cells. They are vascular adhesion molecules expressed on endothelium that can promote cancer metastasis and tumour growth in distant organs [59–62]. They also participate in leukocyte trafficking and their recruitment to inflammatory sites [63]. Modifications in O-glycans, for instance sialylated Lewis structures in colon cancer, that are ligands for E-selectins enhance tumour invasion and metastasis [64]. Furthermore, sTn has been shown to have implications in cell growth and migration. While overexpression of sTn seems to slow cell growth, it increases cell migration and therefore enhances metastasis [65,66]. In addition, the expression of sLe^x antigen in gastric cancer cells induces an increased invasive phenotype through the activation of tyrosine-protein kinase Met, in association with proto-oncogene tyrosine-protein kinase Src, focal adhesion kinase (FAK), cell division control protein 42 homolog (Cdc42), ras-related C3 botulinum toxin substrate 1 (Rac1) and ras homologous protein (RhoA) GTPases activation [67].

Interestingly, α 1-6fucosylation of N-glycans in TGF β catalysed by FUT8 stimulates breast cancer invasion and metastasis [68] promoting the EMT process [69,70]. In addition, GnT-III activity can also drive stem cell expansion to promote growth and invasion of cancer cells by EMT that depends on Notch, Wnt, and TGF β signalling [71]. On the other hand, a microRNA-198-5p that targets FUT8 in non-small cell lung cancer cells inhibits cell migration, invasion, EMT and in vivo metastases [72]. EMT induction also promotes changes in sialylation that alter physico-chemical properties of proteins and allow malignant cells to liberate from tumours and migrate to invade other tissues. For example, when EMT occurs in colon cancer, sialyltransferases expression is upregulated, particularly those involved in the synthesis of sLe^x and sLe^a, that serve as ligands for E-selectin [27]. Moreover, the experimental induction of EMT with TGF β in prostate epithelial cells leads to increased levels of oncofetal fibronectin, with an increased expression of Tn and core 1 structures. In fact, when the glycosyltransferases that mediate the synthesis of these antigens were knocked out, the induction of oncofetal fibronectin by TGF β was inhibited and the migratory cell potentiation was reversed [73].

Heparan sulphate proteoglycans (HSPGs) have also been shown to promote cell-to-cell and cell-to-extracellular matrix adhesions, therefore inhibiting invasion and metastasis [74]. On the other hand, the decrease of HSPG levels, as seen in some cancers, results in the malignant cells being more invasive [37].

3. Mechanisms Altering Glycan Synthesis

Glycan synthesis occurs in a highly regulated sequential or competitive action of different glycosyltransferases and glycosidases [1,3]. Glycosyltransferases synthesise glycan chains, whereas glycosidases hydrolyze specific glycan linkages [1,6]. The expression, activity and subcellular location of these enzymes dictate the overall glycosylation pro-

file in cells or tissues [3]. Since protein glycosylation has a high impact on a wide range of cell biological processes, as described above, changes in glycosidase or glycosyltransferase expression, subcellular localization or activity dictate the glycan motives present in a cell, and can thus modify cell proliferation, adhesion, differentiation and immune responses [1,30,41,42]. While the incomplete synthesis is a phenomenon that occurs in the early stages of cancer progression and leads to the appearance of truncated forms of *O*-glycans (such as Tn or sTn antigens), the neosynthesis takes place in advanced stages of neoplasia and is associated with the induction of genes involved in carbohydrate synthesis, and derives in the formation of *de novo* antigens such as sLe^a or sLe^x [1,30,41,42,75].

A large amount of evidence has demonstrated that incomplete *O*-glycan TACA expression is a consequence of a dysregulation of the initial steps of *O*-glycan biosynthesis mediated by polypeptide-*N*-acetylgalactosaminyl-transferases (ppGalNAcTs) that transfer UDP-GalNAc to Ser/Thr residues in a polypeptide, forming Tn antigen (GalNAc1-Ser/Thr) [17,30]. Indeed, an overexpression, a higher activity or a modified subcellular location of these transferases, as well as defects in the T-synthase or its associated chaperone Cosmc, can lead to higher Tn antigen expression levels [75–82]. On the other hand, an upregulation of GalNAc2,6-sialyltransferase (ST6GalNAc-I) in tumours results in the overexpression of sTn, (NeuAc2,6-GalNAc-Ser/Thr) preventing further *O*-glycan elongation. Indeed, increased activity or expression of sialyltransferases leads to the hypersialylation of cell surfaces, which as stated before is one of the most common glycosylation changes that occurs in tumours [48]. Furthermore, an upregulation of the TF antigen (Gal1,3-GalNAc 1-*O*-Ser/Thr) can be the consequence of upregulation of T-synthase [83]. Interestingly, it would seem that hormone therapy of breast cancer cells and oxidative stress induced the expression of incomplete TACAs in *O*-glycans [84] through a process that still remains to be understood. These cancer-associated glycoantigens are frequently decorating mucins on epithelial tumours.

With respect to *N*-glycan associated TACAs, the overexpression of fucosyltransferases (Fuc-T 1/3) increases terminal fucosylation leading to the expression of Le^x and Le^y [85]. Furthermore, the upregulation of sialyltransferases leads to sialylated species of these antigens (sLe^x and sLe^y), while increased activity levels of the mannoside acetylglucosaminyltransferase 5 (MGAT5) increases *N*-glycan branching [86]. Furthermore, dysregulation of the 4-*N*-acetylgalactosaminyltransferase 3 (β 4GALNT3) leads to the expression of terminal LacdiNAc (GalNAc1,4GlcNAc1-) on both *N*-linked and *O*-linked glycans [87,88]. Finally, an upregulation of different potential polypeptide glycosyltransferase substrates can also upregulate the expression of TACAs in cancer [78,79,82]. Therefore, these reports indicate the complexity of the molecular processes underlying TACA expression in cancer since multiple glycosyltransferases and glycosidases, as well protein expression are involved.

4. Tumour-Associated Glycans Possess Immunomodulatory Properties

The immune system is capable of recognizing malignant cells and inducing effective antitumor immunity able to eradicate cancer cells [89]. The capacity of dendritic cells (DCs) to sense tumour-associated antigens and stimulate naive T cells enables them to initiate the adaptive immune response [90,91]. CD4⁺ T cells are activated via recognition of exogenous derived antigens loaded in major histocompatibility complex class II (MHC II), while CD8⁺ T cells are activated via endogenous derived-antigen loaded in MHC class I (MHC I) by antigen presenting cells, as well as via exogenous-derived antigens loaded in MHC I in a process known as cross-presentation performed by DCs [92,93]. Differentiation of CD4⁺ T cells into T helper-type 1 (Th1) is crucial for the antitumor immune response since they promote IFN γ -mediated cytotoxic mechanisms driven by other cells [94]. Indeed, both cytotoxic CD8⁺ T cells (CTLs) and their innate counterpart, NK cells, can recognize tumour cells and mediate specific killing by cytotoxicity [95]. Apart from NK cells and DCs, other innate cells such as inflammatory M1 macrophages play important roles in tumour eradication [95–97].

Nevertheless, aggressive tumours develop immune evasion mechanisms that protect them from the antitumour immune response by regulating specific effector immunity or inducing other processes such as angiogenesis [98]. Indeed, regulatory T cells (Treg), myeloid-derived suppressor cells (MDSCs), tumour-associated macrophages (TAM) and regulatory DCs, among others, interfere with antitumor immunity and promote tumour growth and metastases development [99]

DCs and TAMs play an essential role in promoting tumour development, being predominantly polarised in the tumour microenvironment to regulatory DCs or alternative activated or M2 macrophages, with anti-inflammatory and proangiogenic functions [100,101]. M2 TAMs also facilitate tissue remodelling and tissue repairing [102]. In addition, the tumour microenvironment is characterised by the expression of immunoregulatory molecules, which are expressed either in cancer cells or leukocytes. Indeed, PD-L1 or PD-L2 expression by tumour cells can inhibit antitumor immunity by interacting with PD1 expressed on cytotoxic T cells and NK cells [97,99,103], causing T cell anergy and inhibit tumoricidal capacity of CTLs [104]. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is another crucial molecule involved in immune regulation in cancer. CTLA-4 is expressed on Tregs and competes with CD28 for binding to costimulatory molecules (CD80 and CD86) on antigen-presenting cells, thereby inhibiting the activation of T cells [105]. Thus, these molecules play a key role in immune regulation and peripheral tolerance [106,107], and their blocking or signalling inhibition constitute one of the most studied antitumor immunotherapy strategies currently [108–112]. Finally, recent reports have demonstrated that the immunological characteristics in the tumour microenvironment also modulate the metabolism of both tumour cells and innate leukocytes, specially DCs and macrophages [113].

4.1. TACAs as Immunomodulators of Antitumor Immunity

Glycan signatures on tumour cells can be recognized by the immune system. In particular, C-type lectin receptors (CLRs) expressed on a variety of leukocytes mediate the interaction between TACAs and the immune system. CLRs consist of a family of one type of transmembrane pattern recognition receptors (PRRs) that recognize glycosylated pathogen-associated molecular patterns (PAMPs) or glycoantigens expressed on tumour cells, among others [114–117]. While CLRs recognise their ligands in a Ca^{2+} -dependent manner, some alternative C-type lectin-like receptors do not need Ca^{2+} for ligand recognition. CLRs can mediate TACA recognition, internalisation, antigen processing and presentation [115]. Furthermore, some of the CLRs can also induce specific signalling, which modulates myeloid cell activation and effector functions, depending on the genetic programmes that they trigger. Indeed, many CLRs contain the signalling motifs immunoreceptor tyrosine-based activation motif (ITAM) or immunoreceptor tyrosine-based inhibitory motif (ITIM) in their cytoplasmic portion, or recruit adaptor proteins that contain ITAM [118]. Other CLRs contain a hemi-ITAM motif composed of a single tyrosine within an YXXL motif [119,120]. However, some CLRs do not trigger cell signalling, although they can mediate antigen internalisation and favour antigen processing and presentation [118]. CLRs can also recognise molecules released by apoptotic or dead cells, also known as damage-associated molecular patterns (DAMPs) and might determine an immunogenic or tolerogenic immune response according to the DAMP recognition-induced signalling pathways [118,121]. Thus, myeloid CLRs are key players in maintaining immune homeostasis or activation and can modulate tumour development, growth or metastasis, as well as pathogen-specific immunity [122].

Some examples of CLRs that recognize TACAs that will be discussed in this review are: Macrophage Mannose Receptor (MMR), Macrophage Galactose/GalNAc lectin (MGL), DC-specific intercellular adhesion molecule-3-grabbing non integrin (DC-SIGN), Macrophage inducible C-type lectin (Mincle), Dendritic cell associated C-type lectin (Dectins) and DC immunoreceptor (DCIR). For instance, CLRs can contain ITAM or ITIM domains and reprogramme cell functions by inducing cytokine production and secretion, oxygen species (ROS) production, favouring antigen processing and presentation, or inhibiting Toll Like Receptor (TLR)-signalling [123]. However, certain TACAs that bind CLRs can only mediate

immunoregulatory mechanisms that help tumours to evade the immune response [124]. Indeed, the incubation of immobilised galactose and mannose-based monosaccharides induces a regulatory phenotype in lipopolysaccharide (LPS)-stimulated DCs, shown by the expression of reduced levels of CD40 and increased PD-L1 and the differentiation of Tregs [125].

Last, sialic acid-binding immunoglobulin-like lectins (Siglecs) are a family of receptors that recognize sialoglycans, including those expressed by tumour cells, such as sTF, sTn and sLe^x antigens, among others. Siglecs mediate immunoregulatory signals both on myeloid and lymphoid immune cells [126], suppressing T cell responses [127] and NK cytotoxicity [128], inducing the expression of TGF β by macrophages [129] and suppressing T cell responses [127]. Of note, a family of soluble lectins known as Galectins plays an important role in the modulation of the antitumor immune response in the tumour microenvironment [130]. Galectins bind to β galactosides and comprise a family with several members that can induce T cell death [131], the secretion of anti-inflammatory factors [132], immunosuppression through PD-1 [133], and angiogenesis [134]. Indeed, T-cell immunoglobulin and mucin domain-containing 3 (TIM-3) binding to its ligand, galectin-9, results in Th1 cell death [135,136]. However, we will not discuss their functions in this work, since this information can be found in recent reviews [137–141].

In addition to these properties, some CLR can collaborate or inhibit other PRR-induced signalling, such as Toll-like receptors (TLRs) [142] or other CLR [143], in a process that is commonly known as crosstalk [144,145]. For example, simultaneous triggering of DC-SIGN with TLR4 strengthens and prolongs TLR-signalling to enhance proinflammatory cytokine production in DCs [146,147]. However, Tn-glycopeptides that bind MGL modulate TLR2 triggering, favouring the production of IL-10 and TNF α by DCs [142]. Furthermore, recent reports have demonstrated that expression of innate receptors can be induced by inflammatory signals, as well as by microRNAs (miRNAs) [148,149], such as DC-SIGN, MGL1 and MMR [150]. Interestingly, both DC-SIGN and MMR-induced by miR-511-3p contribute to the anti-inflammatory DC phenotype defined by increased IL-10 and PD-L1 expression that favours Th2 polarisation via upregulating IL-10 and IL-4 while inhibiting IL-17 [150,151]. Therefore, CLR possess different immunomodulatory properties that regulate immune effector cell functions when expressed on monocytes, macrophages or DCs, among other cells. We describe below the specific mechanisms underlying TACA and membranary CLR interaction that result in the immunomodulation of the antitumor immunity (illustrated in Figure 2).

4.1.1. Dectins

Dectin receptors are a group of CLR that interact with pathogens or cancer cells [152,153]. Several independent works have demonstrated that in cancer, Dectin-1, which binds β glucans in *N*-glycans, can have opposite effects in the induction of antitumor immunity. For instance, it prevents severe metastasis of melanoma or Lewis lung cancer cells by promoting antitumor effector mechanisms mediated by NK cells, DCs or macrophages in a process that depends on Interferon Regulatory Factor (IRF) 5 activation [122], favouring NK cell dependent killing of tumour cells and the recruitment of inflammatory M1 macrophages [152]. It also signals on DCs through the serine/threonine-protein kinase Raf-1 inducing the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) and promoting the differentiation of antitumorigenic Th9 cells [154] and CTLs [155]. In addition, Dectin-1 triggering by β -glucan particles [156] or laminarin [157] suppresses the growth of subcutaneously inoculated Lewis lung cancer and gastric dysplasia, respectively, by inducing MDSC apoptosis and MHC II expression on antigen presenting cells and inhibiting angiogenesis. However, opposite results have demonstrated that Dectin-1 can also promote cancer progression. In fact, it can mediate tolerogenic macrophage programming in collaboration with galectin-9 in pancreatic cancer. Moreover, high expression of Dectin-1 has been associated with cancer and low survival rate [158].

Thus, Dectin-1 is a clear example of a CLR that plays opposing roles in tumour development depending on the microenvironment and aggressiveness of tumours (Figure 2).




Figure 2. TACA recognition by CLRs in cancer. The role of CLRs in TACA recognition is shown: Dectins (yellow background), MMR (pink background), MGL (blue background), DC-SIGN (brown background), Mincle (green background) and DCIR (purple background). Effect of TACA-induced CLR signalling is shown. In red and green lines, the protumorigenic immunomodulatory processes and the antitumor effects, respectively, are represented. Carbohydrate symbol legend is shown in Figure 1.

On the other hand, Dectin -2, which recognizes mainly high mannosylated [159] antigens and is expressed by Kupffer cells, impedes the development of metastasis in the liver induced by colon or melanoma cells by mechanisms where Kupffer cells are able to mediate the uptake and clearance of cancer cells [160]. Therefore, as Dectin-1, Dectin-2 can induce effective antitumor immune responses. Finally, Dectin-2 can form heterodimers with the related CLR Dectin-3 (also known as Macrophage C-type lectin, MCL) [161] and contributes to the suppression of liver metastasis by enhancing the phagocytic activity of Kupffer cells [160] (Figure 2).

4.1.2. MMR

MMR (CD206) is another type of CLR that is mainly expressed on DCs, macrophages and endothelial cells [162], and recognises multivalent mannosylated glycoconjugates both from pathogens and tumour cells [52]. MMR can mediate phagocytosis or endocytosis of its ligands, promoting antigen uptake and presentation to T cells [162]. In addition, MMR expressed on endothelial interacts with lymphocytes and also cancer cells promoting their trafficking [163]. Interestingly, tumours express MMR⁺ TAMs [164], suggesting a role of this molecule in tumour growth. Indeed, MMR is expressed on M2-type macrophages [164], and its expression was associated with a downregulation of IFN γ [164,165] and upregulation of IL-4 [164]. Last, MMR has also been linked to homeostasis through the clearance of hormones and self-proteins [162,163] (Figure 2).

4.1.3. DC-SIGN

DC-SIGN plays an important role in homeostatic control [166], pathogen and tumour derived molecule recognition. DC-SIGN specifically binds antigens decorated with high-mannose or fucosylated Lewis-type structures [167]. As other CLRs, signalling crosstalk with TLRs has been demonstrated for DC-SIGN on DCs [168]. Interestingly, pathogen or tumour recognition by DC-SIGN on DCs often results in immune escape, transforming proinflammatory into tolerogenic signals and keeping them in an immature or tolerogenic state [169,170].

Interestingly, it was recently found that fucosylation of-glycans on pancreatic ductal carcinomas is associated with EMT, being high in epithelial phenotype, while absent in mesenchymal-like cells [171]. It was also proposed that the fucosylated antigens constitute potential ligands for DC-SIGN considering the fact that DC-SIGN⁺ TAMs were recruited to the tumour microenvironment [171], a process that could induce EMT (Figure 2).

4.1.4. Mincle

Mincle (CLEC4E) can either associate with the FcR γ chain or with MCL (Dectin-3), after which Mincle is endocytosed promoting phagocytosis of ligands. Unlike other CLRs, Mincle is expressed on B cells apart from innate cells (macrophages, neutrophils and DCs) [172]. MINCLE recognises glycolipids from pathogens [173] and DAMPs, such as β glucosylceramide and spliceosome-associated protein 130 (SAP130) [174] as well as glycosylated and mannosylated lipids [175]. The recognition of its ligands induces the expression of several cytokines and chemokines such as TNF α , IL-6, MIP-2 and CXCL1 [176–178]. Mincle is expressed on myeloid cells from pancreatic and urothelial cancers [179,180] where it mediates immunosuppression by inducing M2 TAMs and low T cell activation [179,181]. In pancreatic cancer, Mincle triggering by SAP130 induces the recruitment of TAM and promotes tumour growth via necrosome induced-immune suppression [179]. Indeed, silencing of Mincle in tumours effectively blocked the progression of cancer [181] (Figure 2).

4.1.5. DCIR

DCIR (CLEC4a) specifically recognises a broader spectrum of glycan ligands containing fucose and mannose [182,183]. It contains an ITIM, and since its stimulation inhibits the production of inflammatory cytokines, it is thought to participate in the homeostasis and control of inflammation [184–186]. DCIR is differentially expressed on DC depending on their origin and stage of maturation or activation state, being associated with regulatory signals and immature DCs [182]. In addition, DCIR triggering inhibits TLR9-induced IFN α production by plasmacytoid DCs, although it can mediate antigen presentation by endocytosis [186]. DCIR is capable of recognizing tumour cells through sulfo-Le^a, Le^b and Le^a antigens [183], mainly present in *N*-glycans [187] (Figure 2).

4.1.6. MGL

MGL binds terminal GalNAc residues in a calcium-dependent manner and mediates various immune and homeostatic functions [188]. Two very similar MGL isoforms

have been identified in mice, mMGL1 and mMGL2, the latter being the one that presents similar carbohydrate specificity to human MGL [187,189,190]. Both expression and function of MGL have been associated with impaired or tolerogenic immune responses. Not only is MGL expressed in immature or tolerogenic DCs [191], corticosteroid-cultured macrophages [192], alternative activated macrophages or on type 2 DCs [193,194], but its triggering also dampens the immune response, by inducing the production of the anti-inflammatory cytokine IL-10 by DCs [142] and promoting the differentiation of Tregs [142]. In addition, engagement of MGL through effector T cells results in reduced proliferation and induction of T cell apoptosis, suppressing T cell activation [195].

The immunomodulatory role of MGL in cancer can be mediated by recognition of terminal GalNAc residues or the Tn antigen, which are expressed in a variety of tumour-associated proteins such as MUC1, carcinoembryonic antigen (CEA), cancer antigen 15-3 (CA15-3) and receptor tyrosine kinase c-Met, a protein that is involved in colorectal carcinogenesis, among others [196–198]. However, MGL ligands in ovarian tumour cells were not only restricted to mucins attached to the plasmatic membrane but also to intracellular molecules and matrix-associated components [199]. Interestingly, the presence of MGL ligands in colorectal cancer is associated with BRAF mutations and might constitute an independent prognostic marker for advanced colorectal [200–202] and breast cancer [84]. Finally, MGL ligand detection in tumour tissues has been correlated with cell malignancy [201,203–205] and has been proposed for in vivo diagnosis of tumours [206].

MGL seems to play a central role in tumour immunomodulation. Indeed Tn⁺ colorectal gliomas infiltrated with MGL⁺ TAMs are characterised by an enhanced accumulation of MDSCs and reduced levels of cytotoxic CD8⁺ T cells [207]. In addition, our group has recently demonstrated that both lung and breast tumours expressing the Tn antigen contribute to immune evasion by inducing the recruitment of MGL⁺ cells that produce IL-10 and favour the differentiation of tumour-infiltrating Tregs [124,208]. Interestingly, Tn⁺ lung tumour cells also contribute to tumour angiogenesis. Both immune regulation and angiogenesis induced by Tn⁺ tumours is dependent on MGL-expressing myeloid cells [124] (Figure 2).

Interestingly, recent data describing new MGL functions demonstrate that the tolerogenic phenotype in MGL⁺ DCs induced by the interaction between this CLR and its tumour-associated glycan ligands is associated with a metabolic quiescent phenotype in DCs that is characterised by a diminished capacity to use the glycolysis pathway for ATP generation [113].

5. TACAs Relevance in Tumour-Secreted eXtracellular Vesicles

As mediators of intercellular communication, extracellular vesicles (EVs), including microvesicles and exosomes, play vital roles in many aspects of cellular homeostasis, physiology, and pathobiology [209]. In the tumour microenvironment, EVs may derive from cancer cells, immune cells, and also from other non-immune host cells [209], and are key players in the crosstalk between malignant cells and the immune system [210]. Among EVs, we can distinguish microvesicles and exosomes. The main difference among microvesicles (MVs) and exosomes is that MVs are generated by the outward budding and fission of the plasma membrane, while exosomes are secreted when multivesicular bodies fuse with the plasma membrane and release their contents [211,212]. EVs are a main focus of attention in cancer research currently since they can be detected in extracellular fluids such as blood, urine and saliva, and offer a very promising approach for cancer diagnosis.

Some of the tumour-associated glycan alterations have been reported as enriched in cancer EVs, and therefore may constitute important biomarkers with the potential to be used in the clinic [213]. A comprehensive analysis of EV glycosylation compared to cell membrane glycans in human glioma cell lines showed that EVs are enriched in complex N-glycans, containing LacdiNAc structures with di-, tri-, and tetra antennary proximally fucosylated glycans and the presence of peripheral Gal α 3Gal structure, while cellular membranes were highly enriched in high mannose glycans [214]. These results outline the

fact that the glycans found in EVs are not necessarily representative to those present in the glycoconjugates from the cellular membrane.

Another study that characterised the glycan profile of EVs from ovarian cancer cell lines using lectins showed the presence of glycoproteins bearing complex *N*-glycans with 2,3-linked sialic acid, fucose, bisecting-GlcNAc and LacdiNAc structures, and *O*-glycans with the TF antigen [215]. In the same line, EVs from genetically engineered gastric cancer cell lines with truncated *O*-glycosylation contained sTn [216]. Furthermore, EVs from melanoma cells and colon cancer cells express complex *N*-linked glycans, high mannose, polylactosamine, and a reduction in Blood Group A/B antigens [217], as well as the Tn antigen, suggesting that tumour-derived EVs carry TACAs similar to the parental cancer cells that produce them [217] and that they might have a role in tumour progression.

Glycosylation Role in EV Functions

Glycosylation in EVs has a fundamental role in their uptake and signalling by immune cells [218]. Indeed, the release of *N*-glycans in EVs increases their uptake by different types of cells [219]. Furthermore, *N*-linked glycans can determine the EV cargo recruitment [220] by directing protein sorting to membrane microdomains within cells [221].

As far as proteoglycans are concerned, treating human cells with heparanase, an enzyme that trims long HS chains and facilitates clustering of Syndecan, has consequences on protein sorting into EVs [222]. In addition, higher levels of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in exosomes derived from heparanase high expressing cells are in comparison with heparanase low expressing cells, and better mediate spreading of tumour cells and invasion of endothelial cells [222]. Thus, proteoglycans in EVs can play an important role in tumour metastasis and angiogenesis.

Aberrant glycosylation in EVs derived from tumour cells may participate in immune modulation and antitumor immunity by interacting with CLRs, promoting metastases [210]. Indeed, breast cancer-derived EVs with bisecting GlcNAc modifications in the vesicular integrin $\beta 1$ showed a diminished pro-metastatic function in recipient cells [223], and *N*-glycosylation in the I-like domain of this protein was found to be essential for EV-mediated metastasis but not proliferation of recipient cells [224]. In prostate cancer, increased cellular expression of FUT8 reduces the secretion of EVs but increases abundance of proteins associated with metastasis in these vesicles and alters the glycans expressed on the EV-derived glycoproteins [225]. Finally, in colon cancer cells with abnormal *O*-glycosylation, the percentage of CD44 in exosomes is significantly higher than in those derived from normal cells [226]. CD44 is related to many pathophysiological features of carcinomas due to its regulation in signalling pathways, and in this study it is shown that aberrant *O*-glycosylation can regulate expression or delivery of this protein, as *O*-glycan truncated CD44 was mainly released via exosomes instead of participating in cellular biological activities [226].

Finally, there is promising evidence that exploring aberrant glycosylation in tumour-derived EVs may lead to the identification of novel biomarkers for cancer diagnosis. For instance, CD63, an EV marker overexpressed in breast cancer, may be detected in serum through fucose binding lectins [227].

6. TACA and CLR Targeting for Cancer Immunotherapy

Considering the role of TACA in cancer progression, together with the expression and function of CLRs, targeting antigen presenting cells (such as DCs and macrophages) using CLR ligands or specific antibodies is an attractive strategy to recruit and activate these cells. Indeed, specific glycan ligands can activate or suppress downstream signalling of a certain CLR that might regulate DC maturation, migration, antigen uptake, processing, and presentation as well as cytokine production influencing adaptive immune responses [228]. However, the immunomodulatory properties of the targeted CLR must be considered to secure the induction of an inflammatory antitumor immune response. Sometimes, the immune regulatory properties of CLRs can be overridden when they are targeted in combi-

nation with adjuvants such as TLR ligands [229,230] or TACA-specific antibodies [231,232]. In some cases, the induction of tolerance can be reverted with coinjection of anti-CD40 antibodies to activate DCs and to inhibit tumour growth [233,234].

When targeting CLR with glycan ligands, several properties of the ligand have to be taken into consideration, such as the nature and multivalency of the antigen to promote crosslinking. The use of artificial against natural glycan ligands may increase its immunogenicity. In addition, both the spatial orientation of the ligand and the multivalency can enhance affinity of the glycan to CLRs. Specific glycans can be conjugated to tumour antigen peptides, proteins or DNA, incorporated in nanoparticles or liposomes, or even into adenoviruses and lentiviral vectors. On the other hand, antibodies can be conjugated to a variety of antigen formulations. Multiple CLRs show potential in antitumor DC-targeted strategies. Here, we will focus on CLRs that are expressed in the tumour microenvironment and recognize TACAs. We will not, however, discuss the efficacy of TACAs as anti-tumor vaccines [17] but rather as tools to target CLRs. Passive immunotherapy with TACA-specific antibodies or strategies that inhibit Siglecs are reviewed elsewhere [26,235].

MMR in vivo targeting has been extensively studied. Mannose-rich glycan structures conjugated to liposomes [236,237], polyamidoamine dendrimers [238] or polylactide-co-glycolide (PLGA) based nanoparticles [239], results in increased IL-12 with IgG antibodies, enhanced CD4⁺ T and CD8⁺ T cells and protection against tumour upon immunisation [240]. Initially, mannosylated conjugated MUC1 generated both antitumor B and T cell responses in preclinical and clinical studies [241,242]. More recently, MMR-targeting was proposed for TAM modulation with siRNA [243] or DNA-based vaccines [244] to favour photothermal tumour therapy [245], or as carriers of chemotherapeutic drugs [246]. In particular, a recent study showed that mannose-functionalized nanoscaffolds as carriers of chemotherapeutic agents [247] efficiently killed tumours, although more in vivo studies are needed to confirm their efficiency. However, the expression of MMR in other cell types other than macrophages and immature DCs, such as endothelial cells, retinal pigment epithelium, kidney mesangial cells, and tracheal smooth muscle cells [164], makes the in vivo MMR-targeting a challenge.

On the other hand, DC-SIGN targeting using glycoconjugated molecules has also been used to deliver cancer antigens to DCs in order to enhance uptake and antigen presentation for the development of more effective cancer immunotherapies [248–250]. Indeed mannosyl-based dendrimers, liposomes or nanoparticles [229,251–254] or even tumour-specific highly mannosylated peptides conjugated with a TLR7 ligand [229], successfully achieved multivaling presentation and enhanced binding to DC-SIGN. However, it should also be considered that binding affinity to DC-SIGN does not always enhance antigen presentation [229]. Interestingly, tumour-derived EVs can target DC-SIGN expressed on DCs. Indeed, upregulation of high mannose glycans in the tumour cell surface enhanced the EV uptake by DCs through DC-SIGN, facilitating the priming of tumour-specific CD8⁺ cells [255].

DC-targeting through CLR can also enhance immune responses through B cell differentiation allowing the secretion of high levels of antitumor antibodies. For instance, since Dectin-1 is mainly expressed by mouse conventional type 2 DCs that favour CD4⁺ Th differentiation, its targeting with a specific antibody induces strong CD4 T cell differentiation and B cell responses [256]. Furthermore, Dectin-1 targeting can also induce activation of human DCs and antigen-specific CD8⁺ T cells [257]. In the context of cancer, Dectin-1 targeting using free β glucans [258–260] and β glucan-coated gold nanoparticles carrying a MUC4-TF peptide [261] induces strong humoral responses, demonstrated by the presence of high titres of specific antibodies and antigen-recognizing T cells [261]. However, the ability of these antibodies to inhibit tumour growth was not explored, indicating the need to prove their antitumor efficacy.

In the same line, the use of glycosylated dendrimeric molecules carrying the Tn antigen has been successfully used to target dermal DCs through MGL2, favouring capture and processing of glycosylated Tn antigen in vivo and inducing a MHC II-restricted T cell response and expansion of the germinal centre B-cells, therefore generating a strong anti-

tumor immune response [194]. In addition, MGL1 in vivo targeting has been successfully achieved using galactose conjugated PLGA-polymers in an experimental model of colitis [262]. Recently, a multivalent peptide mimetic of GalNAc was reported to inhibit ovarian cancer through MGL2-targeting [263].

As with Dectin-1 and MGL2, DCIR2-targeting with a specific antibody revealed that this receptor induces preferentially CD4⁺ Th2 cell differentiation [264] and robust B cell responses [265]. However, no targeting to this CLR has been performed with glycan ligands, probably due to its broader specificity of fucosylated and mannosylated glycans than other CLRs.

Last, only one report of in vivo targeting to Mincle is available, where the immunomodulatory properties of mannosylated and glucosylated lipid antigens were evaluated [175]. Interestingly, glucosylated ligands resulted in significantly increased levels of IL-2, IFN γ , and IL-17 by splenocytes, while no differences with the control were found when mannosylated ligands were injected. Importantly, the effect of glucosylated ligands was abrogated in Mincle-knockout mice [175], although it is unknown which cells are playing a role in the induced immune response.

7. Novel Immunotherapeutic Strategies Based on TACAs

The identification of the functions that mediate TACAs on cancer cells has led to the development of clinical approaches to treat cancer. A great number of strategies have been developed over the three past decades, though, the majority did not reach FDA approval. However, specific monoclonal antibodies against Tn or sTn-MUC1 and MUC16 glycopeptides and GD2 (dinutuximab) have been approved by the Food and Drug Administration (FDA) for their use in cancer treatment [266–269].

New TACA-based approaches for antitumor immunotherapy are being studied at the moment. These include the engineering of chimeric antigen receptor (CAR) T cells and the production of bispecific antibodies [26,270]. Adoptive transfer of CAR T cells is a promising immunotherapy strategy to treat cancer in an MHC-independent manner that grants activation, proliferation and survival of specific adoptively transferred T cells [271]. GD2-specific CAR T cells have been demonstrated to reach solid tumour sites [272] and to produce IFN γ that reprogrammed the tumour microenvironment [273]. However, intratumoral CAR T cells expressed PD-1, which can limit antitumor efficacy [273]. In fact, the combination of CAR T based immunotherapy with anti-PD1 blockade favours CAR T cell survival [274]. On the other hand, anti-sTF-MUC1 peptide CAR T cells were also developed [275] and reported to induce apoptosis and necrosis of tumour cells [276] associated with the production of proinflammatory cytokines and delaying tumour growth [275].

Bispecific antibodies are engineered antibodies that can simultaneously recognize two different epitopes [277]. However, limited studies provide evidence of the potential of TACA-based bispecific antibodies in cancer. Anti-GD2 and CD3 bispecific antibodies have been successful in tumour cell killing [278,279] and reduced tumour growth by increasing T cell activation and proliferation mediated by monocytes [279]. Similarly, anti-MUC1 and CD3 bispecific antibodies were also capable of inhibiting tumour growth [280], although they have been significantly less studied than anti-GD2 bispecific antibodies [275].

8. Conclusions and Perspectives

TACAs expressed by tumour cells or their derived-EVs, together with CLRs present in innate leukocyte, possess immunomodulatory properties that can favour tumour growth by different molecular and cellular mechanisms. Furthermore, CLRs can be targeted to induce effective antitumor immunity, either using specific antibodies or TACAs. However, the latter remains a challenge due to the broad ligand specificity of some CLRs. In this sense, the elucidation of their role in tumour-induced immune evasion is essential to develop antitumor immune therapeutic strategies. Furthermore, the dual targeting of CLRs combining two different TACA-based molecules could improve the desired antitumor immune response. In some cases, the targeting of CLR together with a proinflammatory

stimulus, such as TLR ligands, is essential to ensure an antitumor response, since many CLRs mediate tolerogenic programmes on antigen presenting cells. Indeed, CLR-targeting to induce antigen-specific tolerance has been recently proposed as a possible strategy to treat inflammatory or autoimmune diseases [281]. Finally, some approaches that could be exploited in the near future need to be further investigated, such as CLR targeting in combination with checkpoint blockade, through the use of anti-PD1 or anti-CTLA4 antibodies, as well as CLR targeting combined with immunogenic chemotherapy. Future research in these areas will certainly provide new insights for CLR-based cancer immunotherapy using TACAs as well as on their roles in cancer.

Author Contributions: Both authors prepared, drafted and revised this work. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Comisión Sectorial de Investigación Científica: I+D 2020-290, Iniciación 2017-220; Grupos-2018-908; Agencia Nacional de Investigación e Innovación: FCE-1-2019-1-156295; Programa de Desarrollo de Ciencias Básicas (PEDECIBA)ing. Comisión Sectorial de Investigación Científica and Agencia Nacional de Investigación Científica and PEDECIBA (Uruguay). CSIC I+D and ANII-FCE to T. F. and CSIC Iniciación to V. C were granted.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ohtsubo, K.; Marth, J.D. Glycosylation in Cellular Mechanisms of Health and Disease. *Cell* **2006**, *126*, 855–867. [[CrossRef](#)] [[PubMed](#)]
2. Moriwaki, K.; Chan, F.K.M.; Miyoshi, E. Sweet modification and regulation of death receptor signalling pathway. *J. Biochem.* **2021**, *169*, 643–652. [[CrossRef](#)]
3. Munkley, J.; Elliott, D. Hallmarks of glycosylation in cancer. *Oncotarget* **2016**, *7*, 35478–35489. [[CrossRef](#)] [[PubMed](#)]
4. Martínez-Morales, P.; Cruz, I.M.; la Cruz, L.R.-D.; Maycotte, P.; Salinas, J.S.R.; Zamora, V.J.V.; Quiroz, C.T.G.; Montiel-Jarquín, A.J.; Vallejo-Ruiz, V. Hallmarks of glycogene expression and glycosylation pathways in squamous and adenocarcinoma cervical cancer. *PeerJ* **2021**, *9*, e12081. [[CrossRef](#)]
5. Peixoto, A.; Relvas-Santos, M.; Azevedo, R.; Santos, L.L.; Ferreira, J.A. Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks. *Front. Oncol.* **2019**, *9*, 380. [[CrossRef](#)]
6. Stowell, S.R.; Ju, T.; Cummings, R.D. Protein Glycosylation in Cancer. *Annu. Rev. Pathol. Mech. Dis.* **2015**, *10*, 473–510. [[CrossRef](#)]
7. Häuselmann, I.; Borsig, L. Altered Tumor-Cell Glycosylation Promotes Metastasis. *Front. Oncol.* **2014**, *4*, 28. [[CrossRef](#)]
8. Gill, D.J.; Clausen, H.; Bard, F. Location, location, location: New insights into O-GalNAc protein glycosylation. *Trends Cell Biol.* **2011**, *21*, 149–158. [[CrossRef](#)] [[PubMed](#)]
9. Veillon, L.; Fakhri, C.; Abou-El-Hassan, H.; Kobeissy, F.; Mechref, Y. Glycosylation Changes in Brain Cancer. *ACS Chem. Neurosci.* **2018**, *9*, 51–72. [[CrossRef](#)]
10. Taniguchi, N.; Ohkawa, Y.; Maeda, K.; Harada, Y.; Nagae, M.; Kizuka, Y.; Ihara, H.; Ikeda, Y. True significance of N-acetylglucosaminyltransferases GnT-III, V and α 1,6 fucosyltransferase in epithelial-mesenchymal transition and cancer. *Mol. Asp. Med.* **2021**, *79*, 100905. [[CrossRef](#)]
11. Zhang, D.; Xie, Q.; Wang, Q.; Wang, Y.; Miao, J.; Li, L.; Zhang, T.; Cao, X.; Li, Y. Mass spectrometry analysis reveals aberrant N-glycans in colorectal cancer tissues. *Glycobiology* **2019**, *29*, 372–384. [[CrossRef](#)] [[PubMed](#)]
12. Yamamoto, E.; Ino, K.; Miyoshi, E.; Shibata, K.; Takahashi, N.; Kajiyama, H.; Nawa, A.; Nomura, S.; Nagasaka, T.; Kikkawa, F. Expression of N-acetylglucosaminyltransferase V in endometrial cancer correlates with poor prognosis. *Br. J. Cancer* **2007**, *97*, 1538–1544. [[CrossRef](#)] [[PubMed](#)]
13. Yamamoto, H.; Swoger, J.; Greene, S.; Saito, T.; Hurh, J.; Sweeley, C.; Leestma, J.; Mkrdichian, E.; Cerullo, L.; Nishikawa, A.; et al. Beta1,6-N-acetylglucosamine-bearing N-glycans in human gliomas: Implications for a role in regulating invasivity. *Cancer Res.* **2000**, *60*, 134–142. [[PubMed](#)]
14. Scott, D.A.; Casadonte, R.; Cardinali, B.; Spruill, L.; Mehta, A.S.; Carli, F.; Simone, N.; Kriegsmann, M.; Del Mastro, L.; Kriegsmann, J.; et al. Increases in Tumor N-Glycan Poly lactosamines Associated with Advanced HER2-Positive and Triple-Negative Breast Cancer Tissues. *Proteom. Clin. Appl.* **2019**, *13*, e1800014. [[CrossRef](#)] [[PubMed](#)]
15. Wandall, H.H.; Nielsen, M.A.I.; King-Smith, S.; de Haan, N.; Bagdonaite, I. Global functions of O-glycosylation: Promises and challenges in O-glycobiology. *FEBS J.* **2021**, *288*, 7183–7212. [[CrossRef](#)]
16. Kudelka, M.R.; Ju, T.; Heimbürg-Molinari, J.; Cummings, R.D. Simple Sugars to Complex Disease—Mucin-Type O-Glycans in Cancer. *Adv. Cancer Res.* **2015**, *126*, 53–135.
17. Beckwith, D.M.; Cudic, M. Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design. *Semin. Immunol.* **2020**, *47*, 101389. [[CrossRef](#)]

18. Baldus, S.E.; Mönig, S.P.; Hanisch, F.G.; Zirbes, T.K.; Flucke, U.; Oelert, S.; Zilkens, G.; Madejczik, B.; Thiele, J.; Schneider, P.M.; et al. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma. *Histopathology* **2002**, *40*, 440–449. [[CrossRef](#)]
19. Gold, D.V.; Modrak, D.E.; Ying, Z.; Cardillo, T.M.; Sharkey, R.M.; Goldenberg, D.M. New MUC1 Serum Immunoassay Differentiates Pancreatic Cancer From Pancreatitis. *J. Clin. Oncol.* **2006**, *24*, 252–258. [[CrossRef](#)]
20. Wang, G.; Lipert, R.J.; Jain, M.; Kaur, S.; Chakraborty, S.; Torres, M.P.; Batra, S.K.; Brand, R.E.; Porter, M.D. Detection of the Potential Pancreatic Cancer Marker MUC4 in Serum Using Surface-Enhanced Raman Scattering. *Anal. Chem.* **2011**, *83*, 2554–2561. [[CrossRef](#)]
21. Kaur, S.; Smith, L.M.; Patel, A.; Menning, M.; Watley, D.C.; Malik, S.S.; Krishn, S.R.; Mallya, K.; Aithal, A.; Sasson, A.R.; et al. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. *Am. J. Gastroenterol.* **2017**, *112*, 172–183. [[CrossRef](#)] [[PubMed](#)]
22. Gubbels, J.A.A.; Felder, M.; Horibata, S.; Belisle, J.A.; Kapur, A.; Holden, H.; Petrie, S.; Migneault, M.; Rancourt, C.; Connor, J.P.; et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. *Mol. Cancer* **2010**, *9*, 11. [[CrossRef](#)] [[PubMed](#)]
23. Chen, S.; Dallas, M.R.; Balzer, E.M.; Konstantopoulos, K. Mucin 16 is a functional selectin ligand on pancreatic cancer cells. *FASEB J.* **2012**, *26*, 1349–1359. [[CrossRef](#)] [[PubMed](#)]
24. Rowson-Hodel, A.R.; Wald, J.H.; Hatakeyama, J.; O’Neal, W.K.; Stonebraker, J.R.; VanderVorst, K.; Saldana, M.J.; Borowsky, A.D.; Sweeney, C.; Carraway, K.L. Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer. *Oncogene* **2018**, *37*, 197–207. [[CrossRef](#)]
25. Hsu, H.-P.; Lai, M.-D.; Lee, J.-C.; Yen, M.-C.; Weng, T.-Y.; Chen, W.-C.; Fang, J.-H.; Chen, Y.-L. Mucin 2 silencing promotes colon cancer metastasis through interleukin-6 signaling. *Sci. Rep.* **2017**, *7*, 5823. [[CrossRef](#)]
26. Mantuano, N.R.; Natoli, M.; Zippelius, A.; Läubli, H. Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy. *J. Immunother. Cancer* **2020**, *8*, e001222. [[CrossRef](#)]
27. Bhide, G.; Colley, K.J. Sialylation of N-glycans: Mechanism, cellular compartmentalization and function. *Histochem. Cell Biol.* **2017**, *147*, 149–174. [[CrossRef](#)]
28. Samraj, A.N.; Pearce, O.M.T.; Läubli, H.; Crittenden, A.N.; Bergfeld, A.K.; Banda, K.; Gregg, C.J.; Bingman, A.E.; Secret, P.; Diaz, S.L.; et al. A red meat-derived glycan promotes inflammation and cancer progression. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 542–547. [[CrossRef](#)]
29. Läubli, H.; Kawanishi, K.; Vazhappilly, C.G.; Matar, R.; Merheb, M.; Siddiqui, S.S. Tools to study and target the Siglec–sialic acid axis in cancer. *FEBS J.* **2021**, *288*, 6206–6225. [[CrossRef](#)]
30. Pinho, S.S.; Reis, C.A. Glycosylation in cancer: Mechanisms and clinical implications. *Nat. Rev. Cancer* **2015**, *15*, 540–555. [[CrossRef](#)]
31. Tang, H.; Partyka, K.; Hsueh, P.; Sinha, J.Y.; Kletter, D.; Zeh, H.; Huang, Y.; Brand, R.E.; Haab, B.B. Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9. *Cell. Mol. Gastroenterol. Hepatol.* **2016**, *2*, 201–221.e15. [[CrossRef](#)] [[PubMed](#)]
32. Barnett, D.; Liu, Y.; Partyka, K.; Huang, Y.; Tang, H.; Hostetter, G.; Brand, R.E.; Singhi, A.D.; Drake, R.R.; Haab, B.B. The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells. *Sci. Rep.* **2017**, *7*, 4020. [[CrossRef](#)] [[PubMed](#)]
33. Kopitz, J. Lipid glycosylation: A primer for histochemists and cell biologists. *Histochem. Cell Biol.* **2017**, *147*, 175–198. [[CrossRef](#)] [[PubMed](#)]
34. Prydz, K. Determinants of Glycosaminoglycan (GAG) Structure. *Biomolecules* **2015**, *5*, 2003–2022. [[CrossRef](#)]
35. Reily, C.; Stewart, T.J.; Renfrow, M.B.; Novak, J. Glycosylation in health and disease. *Nat. Rev. Nephrol.* **2019**, *15*, 346–366. [[CrossRef](#)]
36. Ghiselli, G. Drug-Mediated Regulation of Glycosaminoglycan Biosynthesis. *Med. Res. Rev.* **2017**, *37*, 1051–1094. [[CrossRef](#)]
37. Sanderson, R.D. Heparan sulfate proteoglycans in invasion and metastasis. *Semin. Cell Dev. Biol.* **2001**, *12*, 89–98. [[CrossRef](#)]
38. Marolla, A.P.C.; Waisberg, J.; Saba, G.T.; Waisberg, D.R.; Margeotto, F.B.; Pinhal, M.A.D.S. Glycomics expression analysis of sulfated glycosaminoglycans of human colorectal cancer tissues and non-neoplastic mucosa by electrospray ionization mass spectrometry. *Einstein (Sao Paulo)* **2015**, *13*, 510–517. [[CrossRef](#)]
39. Crespo, A.; García-Suárez, O.; Fernández-Vega, I.; Solis-Hernandez, M.P.; García, B.; Castañón, S.; Quirós, L.M. Heparan sulfate proteoglycans undergo differential expression alterations in left sided colorectal cancer, depending on their metastatic character. *BMC Cancer* **2018**, *18*, 687. [[CrossRef](#)]
40. Varki, A.; Gagneux, P. Biological functions of glycans. In *Essentials of Glycobiology*, 3rd ed.; Cold Spring Harbor: Cold Spring Harbor, NY, USA, 2015; pp. 77–88.
41. Varki, A.; Kannagi, R.; Toole, B.; Stanley, P. Glycosylation changes in cancer. In *Essentials of Glycobiology*, 3rd ed.; Cold Spring Harbor: Cold Spring Harbor, NY, USA, 2015; pp. 597–609.
42. Rodrigues, J.G.; Balmaña, M.; Macedo, J.A.; Poças, J.; Fernandes, Â.; De-Freitas-Junior, J.C.M.; Pinho, S.S.; Gomes, J.; Magalhães, A.; Gomes, C.; et al. Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis. *Cell. Immunol.* **2018**, *333*, 46–57. [[CrossRef](#)]
43. Gao, Z.; Xu, M.; Yue, S.; Shan, H.; Xia, J.; Jiang, J.; Yang, S. Abnormal sialylation and fucosylation of saliva glycoproteins: Characteristics of lung cancer-specific biomarkers. *Curr. Res. Pharmacol. Drug Discov.* **2022**, *3*, 100079. [[CrossRef](#)] [[PubMed](#)]

44. Lan, Y.; Hao, C.; Zeng, X.; He, Y.; Zeng, P.; Guo, Z.; Zhang, L. Serum glycoprotein-derived N- and O-linked glycans as cancer biomarkers. *Am. J. Cancer Res.* **2016**, *6*, 2390–2415. [[PubMed](#)]
45. Gilgunn, S.; Conroy, P.J.; Saldova, R.; Rudd, P.M.; O’Kennedy, R.J. Aberrant PSA glycosylation—A sweet predictor of prostate cancer. *Nat. Rev. Urol.* **2013**, *10*, 99–107. [[CrossRef](#)] [[PubMed](#)]
46. Ferrer-Batallé, M.; Llop, E.; Ramírez, M.; Aleixandre, R.N.; Saez, M.; Comet, J.; De Llorens, R.; Peracaula, R. Comparative Study of Blood-Based Biomarkers, α 2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection. *Int. J. Mol. Sci.* **2017**, *18*, 845. [[CrossRef](#)] [[PubMed](#)]
47. Hashiguchi, Y.; Kasai, M.; Fukuda, T.; Ichimura, T.; Yasui, T.; Sumi, T. Serum Sialyl-Tn (STN) as a Tumor Marker in Patients with Endometrial Cancer. *Pathol. Oncol. Res.* **2016**, *22*, 501–504. [[CrossRef](#)]
48. Hugonnet, M.; Singh, P.; Haas, Q.; von Gunten, S. The Distinct Roles of Sialyltransferases in Cancer Biology and Onco-Immunology. *Front. Immunol.* **2021**, *12*, 799861. [[CrossRef](#)]
49. Wang, Y.-N.; Lee, H.-H.; Hsu, J.L.; Yu, D.; Hung, M.-C. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. *J. Biomed. Sci.* **2020**, *27*, 77. [[CrossRef](#)]
50. Li, C.-W.; Lim, S.-O.; Chung, E.M.; Kim, Y.-S.; Park, A.H.; Yao, J.; Cha, J.-H.; Xia, W.; Chan, L.-C.; Kim, T.; et al. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. *Cancer Cell* **2018**, *33*, 187–201.e10. [[CrossRef](#)]
51. Lau, K.; Partridge, E.A.; Grigorian, A.; Silvescu, C.I.; Reinhold, V.N.; Demetriou, M.; Dennis, J.W. Complex N-Glycan Number and Degree of Branching Cooperate to Regulate Cell Proliferation and Differentiation. *Cell* **2007**, *129*, 123–134. [[CrossRef](#)]
52. Loke, I.; Kolarich, D.; Packer, N.H.; Thaysen-Andersen, M. Emerging roles of protein mannosylation in inflammation and infection. *Mol. Asp. Med.* **2016**, *51*, 31–55. [[CrossRef](#)]
53. Gupta, V.; Bhinge, K.N.; Hosain, S.B.; Xiong, K.; Gu, X.; Shi, R.; Ho, M.-Y.; Khoo, K.-H.; Li, S.-C.; Li, Y.-T.; et al. Ceramide Glycosylation by Glucosylceramide Synthase Selectively Maintains the Properties of Breast Cancer Stem Cells. *J. Biol. Chem.* **2012**, *287*, 37195–37205. [[CrossRef](#)] [[PubMed](#)]
54. Ibrahim, S.A.; Gadalla, R.; El-Ghonaimy, E.A.; Samir, O.; Mohamed, H.T.; Hassan, H.; Greve, B.; El-Shinawi, M.; Mohamed, M.M.; Götte, M. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways. *Mol. Cancer* **2017**, *16*, 57. [[CrossRef](#)] [[PubMed](#)]
55. Sagar, S.; Leiphrakpam, P.D.; Thomas, D.; McAndrews, K.L.; Caffrey, T.C.; Swanson, B.J.; Clausen, H.; Wandall, H.H.; Hollingsworth, M.A.; Radhakrishnan, P. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans. *Cancer Lett.* **2021**, *503*, 91–102. [[CrossRef](#)] [[PubMed](#)]
56. Gu, J.; Isaji, T.; Xu, Q.; Kariya, Y.; Gu, W.; Fukuda, T.; Du, Y. Potential roles of N-glycosylation in cell adhesion. *Glycoconj. J.* **2012**, *29*, 599–607. [[CrossRef](#)]
57. Pinho, S.S.; Reis, C.A.; Paredes, J.; Magalhães, A.M.; Ferreira, A.C.; Figueiredo, J.; Xiaogang, W.; Carneiro, F.; Gärtner, F.; Seruca, R. The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. *Hum. Mol. Genet.* **2009**, *18*, 2599–2608. [[CrossRef](#)]
58. Raghu, D.; Mobley, R.J.; Shendy, N.A.; Perry, C.H.; Abell, A.N. GALNT3 Maintains the Epithelial State in Trophoblast Stem Cells. *Cell Rep.* **2019**, *26*, 3684–3697.e7. [[CrossRef](#)]
59. Laubli, H.; Borsig, L. Selectins promote tumor metastasis. *Semin. Cancer Biol.* **2010**, *20*, 169–177. [[CrossRef](#)]
60. Ganesh, D.; Jain, P.; Shanthamurthy, C.D.; Toraskar, S.; Kikkeri, R. Targeting Selectins Mediated Biological Activities with Multivalent Probes. *Front. Chem.* **2021**, *9*, 773027. [[CrossRef](#)]
61. Tinoco, R.; Carrette, F.; Barraza, M.L.; Otero, D.C.; Magaña, J.; Bosenberg, M.W.; Swain, S.L.; Bradley, L.M. PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion. *Immunity* **2016**, *44*, 1470. [[CrossRef](#)]
62. Matsumoto, M.; Miyasaka, M.; Hirata, T. P-Selectin Glycoprotein Ligand-1 Negatively Regulates T-Cell Immune Responses. *J. Immunol.* **2009**, *183*, 7204–7211. [[CrossRef](#)]
63. Na Kim, H.; Ruan, Y.; Ogana, H.; Kim, Y.-M. Cadherins, Selectins, and Integrins in CAM-DR in Leukemia. *Front. Oncol.* **2020**, *10*, 592733. [[CrossRef](#)] [[PubMed](#)]
64. Brockhausen, I. Mucin-type O-glycans in human colon and breast cancer: Glycodynamics and functions. *EMBO Rep.* **2006**, *7*, 599–604. [[CrossRef](#)] [[PubMed](#)]
65. Julien, S.; Adriaenssens, E.; Ottenberg, K.; Furlan, A.; Courtand, G.; Vercoutter-Edouart, A.-S.; Hanisch, F.-G.; Delannoy, P.; Le Bourhis, X. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumorigenicity. *Glycobiology* **2006**, *16*, 54–64. [[CrossRef](#)] [[PubMed](#)]
66. Julien, S.; Lagadec, C.; Krzewinski-Recchi, M.-A.; Courtand, G.; Le Bourhis, X.; Delannoy, P. Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration. *Breast Cancer Res. Treat.* **2005**, *90*, 77–84. [[CrossRef](#)]
67. Gomes, C.; Osório, H.; Pinto, M.T.; Campos, D.; Oliveira, M.J.; Reis, C.A. Expression of ST3GAL4 leads to SLe(x) expression and induces c-Met activation and an invasive phenotype in gastric carcinoma cells. *PLoS ONE* **2013**, *8*, e66737. [[CrossRef](#)]
68. Tu, C.F.; Wu, M.Y.; Lin, Y.C.; Kannagi, R.; Yang, R.B. FUT8 promotes breast cancer cell invasiveness by remodeling TGF-beta receptor core fucosylation. *Breast Cancer Res.* **2017**, *19*, 111. [[CrossRef](#)]
69. Bastian, K.; Scott, E.; Elliott, D.J.; Munkley, J. FUT8 Alpha-(1,6)-Fucosyltransferase in Cancer. *Int. J. Mol. Sci.* **2021**, *22*, 455. [[CrossRef](#)]

70. Yang, H.F.; Yu, M.; Jin, H.D.; Yao, J.Q.; Lu, Z.L.; Yabasin, I.B.; Yan, Q.; Wen, Q.P. Fentanyl Promotes Breast Cancer Cell Stemness and Epithelial-Mesenchymal Transition by Upregulating alpha1, 6-Fucosylation via Wnt/beta-Catenin Signaling Pathway. *Front. Physiol.* **2017**, *8*, 510. [[CrossRef](#)]
71. Allam, H.; Aoki, K.; Benigno, B.B.; McDonald, J.F.; Mackintosh, S.G.; Tiemeyer, M.; Abbott, K.L. Glycomic Analysis of Membrane Glycoproteins with Bisecting Glycosylation from Ovarian Cancer Tissues Reveals Novel Structures and Functions. *J. Proteome Res.* **2015**, *14*, 434–446. [[CrossRef](#)]
72. Wang, S.; Zhang, X.; Yang, C.; Xu, S. MicroRNA-198-5p inhibits the migration and invasion of non-small lung cancer cells by targeting fucosyltransferase 8. *Clin. Exp. Pharmacol. Physiol.* **2019**, *46*, 955–967. [[CrossRef](#)]
73. Lange, T.; Samatov, T.R.; Tonevitsky, A.G.; Schumacher, U. Importance of altered glycoprotein-bound N- and O-glycans for epithelial-to-mesenchymal transition and adhesion of cancer cells. *Carbohydr. Res.* **2014**, *389*, 39–45. [[CrossRef](#)] [[PubMed](#)]
74. Morla, S. Glycosaminoglycans and Glycosaminoglycan Mimetics in Cancer and Inflammation. *Int. J. Mol. Sci.* **2019**, *20*, 1963. [[CrossRef](#)] [[PubMed](#)]
75. Freire, T.; Osinaga, E. The sweet side of tumor immunotherapy. *Immunotherapy* **2012**, *4*, 719–734. [[CrossRef](#)] [[PubMed](#)]
76. Ju, T.; Lanneau, G.S.; Gautam, T.; Wang, Y.; Xia, B.; Stowell, S.R.; Willard, M.T.; Wang, W.; Xia, J.Y.; Zuna, R.E.; et al. Human Tumor Antigens Tn and Sialyl Tn Arise from Mutations in Cosmc. *Cancer Res.* **2008**, *68*, 1636–1646. [[CrossRef](#)]
77. Yoo, N.J.; Kim, M.S.; Lee, S.H. Absence of COSMC gene mutations in breast and colorectal carcinomas. *APMIS* **2008**, *116*, 154–155. [[CrossRef](#)]
78. Raman, J.; Guan, Y.; Perrine, C.L.; Gerken, T.A.; Tabak, L.A. UDP-N-acetyl- α -d-galactosamine:polypeptide N-acetylgalactosaminyl transferases: Completion of the family tree. *Glycobiology* **2012**, *22*, 768–777; Erratum in *Glycobiology* **2015**, *25*, 465. [[CrossRef](#)]
79. Li, Z.; Yamada, S.; Inenaga, S.; Imamura, T.; Wu, Y.; Wang, K.-Y.; Shimajiri, S.; Nakano, R.; Izumi, H.; Kohno, K.; et al. Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. *Br. J. Cancer* **2011**, *104*, 1882–1889. [[CrossRef](#)]
80. Guda, K.; Moinova, H.; He, J.; Jamison, O.; Ravi, L.; Natale, L.; Lutterbaugh, J.; Lawrence, E.; Lewis, S.; Willson, J.K.V.; et al. Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 12921–12925. [[CrossRef](#)]
81. Peng, R.-Q.; Wan, H.-Y.; Li, H.-F.; Liu, M.; Li, X.; Tang, H. MicroRNA-214 Suppresses Growth and Invasiveness of Cervical Cancer Cells by Targeting UDP-N-acetyl- α -d-galactosamine:Polypeptide N-Acetylgalactosaminyltransferase 7. *J. Biol. Chem.* **2012**, *287*, 14301–14309. [[CrossRef](#)]
82. Park, J.-H.; Nishidate, T.; Kijima, K.; Ohashi, T.; Takegawa, K.; Fujikane, T.; Hirata, K.; Nakamura, Y.; Katagiri, T. Critical Roles of Mucin 1 Glycosylation by Transactivated Polypeptide N-acetylgalactosaminyltransferase 6 in Mammary Carcinogenesis. *Cancer Res.* **2010**, *70*, 2759–2769. [[CrossRef](#)] [[PubMed](#)]
83. Wan, Y.; Yu, L.-G. Expression and Impact of C1GalT1 in Cancer Development and Progression. *Cancers* **2021**, *13*, 6305. [[CrossRef](#)] [[PubMed](#)]
84. Kurze, A.-K.; Buhs, S.; Eggert, D.; Oliveira-Ferrer, L.; Müller, V.; Niendorf, A.; Wagener, C.; Nollau, P. Immature O-glycans recognized by the macrophage glycoreceptor CLEC10A (MGL) are induced by 4-hydroxy-tamoxifen, oxidative stress and DNA-damage in breast cancer cells. *Cell Commun. Signal.* **2019**, *17*, 107. [[CrossRef](#)] [[PubMed](#)]
85. Dall’Olio, F.; Pucci, M.; Malagolini, N. The Cancer-Associated Antigens Sialyl Lewis(a/x) and Sd(a): Two Opposite Faces of Terminal Glycosylation. *Cancers* **2021**, *13*, 5273. [[CrossRef](#)]
86. Indellicato, R.; Zulueta, A.; Caretti, A.; Trinchera, M. Complementary Use of Carbohydrate Antigens Lewis a, Lewis b, and Sialyl-Lewis a (CA19.9 Epitope) in Gastrointestinal Cancers: Biological Rationale towards a Personalized Clinical Application. *Cancers* **2020**, *12*, 1509. [[CrossRef](#)]
87. Hirano, K.; Matsuda, A.; Shirai, T.; Furukawa, K. Expression of LacdiNAc Groups on N-Glycans among Human Tumors Is Complex. *BioMed Res. Int.* **2014**, *2014*, 981627. [[CrossRef](#)]
88. Jin, C.; Kenny, D.T.; Skoog, E.C.; Padra, M.; Adamczyk, B.; Vitzeva, V.; Thorell, A.; Venkatakrishnan, V.; Lindén, S.K.; Karlsson, N.G. Structural diversity of human gastric mucin glycans. *Mol. Cell. Proteom.* **2017**, *16*, 743–758. [[CrossRef](#)]
89. Smith, P.L.; Piadel, K.; Dalgleish, A.G. Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy. *Vaccines* **2021**, *9*, 1392. [[CrossRef](#)]
90. Fasano, R.; Shadbad, M.A.; Brunetti, O.; Argentiero, A.; Calabrese, A.; Nardulli, P.; Calbi, R.; Baradaran, B.; Silvestris, N. Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. *Life* **2021**, *11*, 1355. [[CrossRef](#)]
91. Nava, S.; Lisini, D.; Frigerio, S.; Bersano, A. Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect. *Int. J. Mol. Sci.* **2021**, *22*, 12339. [[CrossRef](#)]
92. Basu, A.; Ramamoorthi, G.; Albert, G.; Gallen, C.; Beyer, A.; Snyder, C.; Koski, G.; Disis, M.L.; Czerniecki, B.J.; Kodumudi, K. Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy. *Front. Immunol.* **2021**, *12*, 669474. [[CrossRef](#)] [[PubMed](#)]
93. Mantel, I.; Sadiq, B.A.; Blander, J.M. Spotlight on TAP and its vital role in antigen presentation and cross-presentation. *Mol. Immunol.* **2022**, *142*, 105–119. [[CrossRef](#)] [[PubMed](#)]
94. Matsuo, K.; Yoshie, O.; Nakayama, T. Multifaceted Roles of Chemokines and Chemokine Receptors in Tumor Immunity. *Cancers* **2021**, *13*, 6132. [[CrossRef](#)]

95. Borst, J.; Ahrends, T.; Bąbała, N.; Melief, C.J.M.; Kastenmüller, W. CD4+ T cell help in cancer immunology and immunotherapy. *Nat. Rev. Immunol.* **2018**, *18*, 635–647. [[CrossRef](#)] [[PubMed](#)]
96. Chiossone, L.; Dumas, P.-Y.; Vienne, M.; Vivier, E. Natural killer cells and other innate lymphoid cells in cancer. *Nat. Rev. Immunol.* **2018**, *18*, 671–688, Correction in *Nat. Rev. Immunol.* **2018**, *18*, 726. <https://doi.org/10.1038/s41577-018-0077-4>. [[CrossRef](#)] [[PubMed](#)]
97. Vacca, P.; Munari, E.; Tumino, N.; Moretta, F.; Pietra, G.; Vitale, M.; Del Zotto, G.; Mariotti, F.R.; Mingari, M.C.; Moretta, L. Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes? *Immunol. Lett.* **2018**, *201*, 14–19. [[CrossRef](#)]
98. Kwiecień, I.; Rutkowska, E.; Raniszewska, A.; Rzepecki, P.; Domagała-Kulawik, J. Modulation of the immune response by heterogeneous monocytes and dendritic cells in lung cancer. *World J. Clin. Oncol.* **2021**, *12*, 966–982. [[CrossRef](#)]
99. Kitamura, T.; Qian, B.-Z.; Pollard, J.W. Immune cell promotion of metastasis. *Nat. Rev. Immunol.* **2015**, *15*, 73–86. [[CrossRef](#)]
100. Tucci, M.; Passarelli, A.; Mannavola, F.; Felici, C.; Stucci, L.S.; Cives, M.; Silvestris, F. Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. *Front. Oncol.* **2019**, *9*, 1148. [[CrossRef](#)]
101. Malekghasemi, S.; Majidi, J.; Baghbanzadeh, A.; Abdolalizadeh, J.; Baradaran, B.; Aghebati-Maleki, L. Tumor-Associated Macrophages: Protumoral Macrophages in Inflammatory Tumor Microenvironment. *Adv. Pharm. Bull.* **2020**, *10*, 556–565. [[CrossRef](#)] [[PubMed](#)]
102. Chen, Y.; Song, Y.; Du, W.; Gong, L.; Chang, H.; Zou, Z. Tumor-associated macrophages: An accomplice in solid tumor progression. *J. Biomed. Sci.* **2019**, *26*, 78. [[CrossRef](#)] [[PubMed](#)]
103. Palicelli, A.; Croci, S.; Bisagni, A.; Zanetti, E.; De Biase, D.; Melli, B.; Sanguedolce, F.; Ragazzi, M.; Zanelli, M.; Chaux, A.; et al. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment. *Int. J. Mol. Sci.* **2021**, *22*, 12330. [[CrossRef](#)] [[PubMed](#)]
104. Kornepati, A.V.R.; Vadlamudi, R.K.; Curiel, T.J. Programmed death ligand 1 signals in cancer cells. *Nat. Rev. Cancer* **2022**, *22*, 174–189; Correction in *Nat. Cancer* **2022**, *22*, 190. [[CrossRef](#)]
105. Ribas, A.; Wolchok, J.D. Cancer immunotherapy using checkpoint blockade. *Science* **2018**, *359*, 1350–1355. [[CrossRef](#)]
106. Dai, S.; Jia, R.; Zhang, X.; Fang, Q.; Huang, L. The PD-1/PD-Ls pathway and autoimmune diseases. *Cell. Immunol.* **2014**, *290*, 72–79. [[CrossRef](#)]
107. Patsoukis, N.; Wang, Q.; Strauss, L.; Boussiotis, V.A. Revisiting the PD-1 pathway. *Sci. Adv.* **2020**, *6*, eabd2712. [[CrossRef](#)]
108. Kim, M.J.; Ha, S.-J. Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy. *Front. Cell Dev. Biol.* **2021**, *9*, 767466. [[CrossRef](#)]
109. Zhou, C.; Liu, Q.; Xiang, Y.; Gou, X.; Li, W. Role of the tumor immune microenvironment in tumor immunotherapy (Review). *Oncol. Lett.* **2022**, *23*, 53. [[CrossRef](#)]
110. Vafaei, S.; Zekiy, A.O.; Khanamir, R.A.; Zaman, B.A.; Ghayourvahdat, A.; Azimizonuzi, H.; Zamani, M. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. *Cancer Cell Int.* **2022**, *22*, 2. [[CrossRef](#)] [[PubMed](#)]
111. Taefehshokr, S.; Parhizkar, A.; Hayati, S.; Mousapour, M.; Mahmoudpour, A.; Eleid, L.; Rahmanpour, D.; Fattahi, S.; Shabani, H.; Taefehshokr, N. Cancer immunotherapy: Challenges and limitations. *Pathol. Res. Pract.* **2022**, *229*, 153723. [[CrossRef](#)] [[PubMed](#)]
112. Korman, A.J.; Garrett-Thomson, S.C.; Lonberg, N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. *Nat. Rev. Drug Discov.* **2021**. Correction in *Nat. Rev. Drug Discov.* **2022**, *21*, 163. <https://doi.org/10.1038/s41573-022-00393-8>. [[CrossRef](#)] [[PubMed](#)]
113. Zaal, A.; Li, R.E.; Lubbers, J.; Bruijns, S.C.M.; Kalay, H.; Van Kooyk, Y.; Van Vliet, S.J. Activation of the C-Type Lectin MGL by Terminal GalNAc Ligands Reduces the Glycolytic Activity of Human Dendritic Cells. *Front. Immunol.* **2020**, *11*, 305. [[CrossRef](#)]
114. Tang, C.; Makusheva, Y.; Sun, H.; Han, W.; Iwakura, Y. Myeloid C-type lectin receptors in skin/mucoepithelial diseases and tumors. *J. Leukoc. Biol.* **2019**, *106*, 903–917. [[CrossRef](#)]
115. Valverde, P.; Martinez, J.D.; Canada, F.J.; Arda, A.; Jimenez-Barbero, J. Molecular Recognition in C-Type Lectins: The Cases of DC-SIGN, Langerin, MGL, and L-Sectin. *ChemBioChem* **2020**, *21*, 2999–3025. [[CrossRef](#)]
116. Nonaka, M.; Ma, B.Y.; Murai, R.; Nakamura, N.; Baba, M.; Kawasaki, N.; Hodohara, K.; Asano, S.; Kawasaki, T. Glycosylation-Dependent Interactions of C-Type Lectin DC-SIGN with Colorectal Tumor-Associated Lewis Glycans Impair the Function and Differentiation of Monocyte-Derived Dendritic Cells. *J. Immunol.* **2008**, *180*, 3347–3356. [[CrossRef](#)]
117. Drummond, R.; Dambuza, I.M.; Vautier, S.; A Taylor, J.; Reid, D.M.; Bain, C.; Underhill, D.; Masopust, D.; Kaplan, D.H.; Brown, G.D. CD4+ T-cell survival in the GI tract requires dectin-1 during fungal infection. *Mucosal Immunol.* **2016**, *9*, 492–502. [[CrossRef](#)]
118. Mayer, S.; Raulf, M.-K.; Lepenies, B. C-type lectins: Their network and roles in pathogen recognition and immunity. *Histochem. Cell Biol.* **2017**, *147*, 223–237. [[CrossRef](#)]
119. Robinson, M.J.; Sancho, D.; Slack, E.C.; LeibundGut-Landmann, S.; Sousa, C.R.E. Myeloid C-type lectins in innate immunity. *Nat. Immunol.* **2006**, *7*, 1258–1265. [[CrossRef](#)] [[PubMed](#)]
120. Osorio, F.; Reis e Sousa, C. Myeloid C-type lectin receptors in pathogen recognition and host defense. *Immunity* **2011**, *34*, 651–664. [[CrossRef](#)] [[PubMed](#)]
121. Drouin, M.; Saenz, J.; Chiffolleau, E. C-Type Lectin-Like Receptors: Head or Tail in Cell Death Immunity. *Front. Immunol.* **2020**, *11*, 251. [[CrossRef](#)] [[PubMed](#)]

122. Chiba, S.; Ikushima, H.; Ueki, H.; Yanai, H.; Kimura, Y.; Hangai, S.; Nishio, J.; Negishi, H.; Tamura, T.; Saijo, S.; et al. Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses. *eLife* **2014**, *3*, e04177. [[CrossRef](#)] [[PubMed](#)]
123. Tone, K.; Stappers, M.H.; Willment, J.A.; Brown, G.D. C-type lectin receptors of the Dectin-1 cluster: Physiological roles and involvement in disease. *Eur. J. Immunol.* **2019**, *49*, 2127–2133. [[CrossRef](#)] [[PubMed](#)]
124. da Costa, V.; van Vliet, S.J.; Carasi, P.; Frigerio, S.; García, P.A.; Croci, D.O.; Festari, M.F.; Costa, M.; Landeira, M.; Rodríguez-Zraquia, S.A.; et al. The Tn antigen promotes lung tumor growth by fostering immunosuppression and angiogenesis via interaction with Macrophage Galactose-type lectin 2 (MGL2). *Cancer Lett.* **2021**, *518*, 72–81. [[CrossRef](#)] [[PubMed](#)]
125. Alobaid, M.; Richards, S.-J.; Alexander, M.; Gibson, M.; Ghaemmaghami, A. Developing immune-regulatory materials using immobilized monosaccharides with immune-instructive properties. *Mater. Today Bio* **2020**, *8*, 100080. [[CrossRef](#)] [[PubMed](#)]
126. Rodríguez, E.; Schetters, S.T.T.; Van Kooyk, Y. The tumour glyco-code as a novel immune checkpoint for immunotherapy. *Nat. Rev. Immunol.* **2018**, *18*, 204–211. [[CrossRef](#)]
127. Wang, J.; Sun, J.; Liu, L.N.; Flies, D.B.; Nie, X.; Toki, M.; Zhang, J.; Song, C.; Zarr, M.; Zhou, X.; et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. *Nat. Med.* **2019**, *25*, 656–666. [[CrossRef](#)]
128. Zheng, Y.; Ma, X.; Su, D.; Zhang, Y.; Yu, L.; Jiang, F.; Zhou, X.; Feng, Y.; Ma, F. The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression. *J. Immunol. Res.* **2020**, *2020*, 6243819. [[CrossRef](#)]
129. Takamiya, R.; Ohtsubo, K.; Takamatsu, S.; Taniguchi, N.; Angata, T. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-beta secretion from monocytes/macrophages through the DAP12-Syk pathway. *Glycobiology* **2013**, *23*, 178–187. [[CrossRef](#)]
130. Modenutti, C.; Capurro, J.I.B.; Di Lella, S.; Martí, M.A. The Structural Biology of Galectin-Ligand Recognition: Current Advances in Modeling Tools, Protein Engineering, and Inhibitor Design. *Front. Chem.* **2019**, *7*, 823. [[CrossRef](#)]
131. Stillman, B.N.; Hsu, D.K.; Pang, M.; Brewer, C.F.; Johnson, P.; Liu, F.-T.; Baum, L.G. Galectin-3 and Galectin-1 Bind Distinct Cell Surface Glycoprotein Receptors to Induce T Cell Death. *J. Immunol.* **2006**, *176*, 778–789. [[CrossRef](#)]
132. Cagnoni, A.J.; Giribaldi, M.L.; Blidner, A.G.; Cutine, A.M.; Gatto, S.G.; Morales, R.M.; Salatino, M.; Abba, M.C.; Croci, D.O.; Mariño, K.V.; et al. Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8⁺ regulatory T cells. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2102950118. [[CrossRef](#)]
133. Curti, B.D.; Koguchi, Y.; Leidner, R.S.; Rolig, A.S.; Sturgill, E.R.; Sun, Z.; Wu, Y.; Rajamanickam, V.; Bernard, B.; Hilgart-Martiszus, I.; et al. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. *J. Immunother. Cancer* **2021**, *9*, e002371. [[CrossRef](#)]
134. Croci, D.O.; Cerliani, J.P.; Dalotto-Moreno, T.; Méndez-Huergo, S.P.; Mascanfroni, I.D.; Dergan-Dylon, S.; Toscano, M.; Caramelo, J.J.; García-Vallejo, J.J.; Ouyang, J.; et al. Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors. *Cell* **2014**, *156*, 744–758. [[CrossRef](#)]
135. Zhu, C.; Anderson, A.C.; Schubart, A.; Xiong, H.; Imitola, J.; Khoury, S.; Zheng, X.X.; Strom, T.B.; Kuchroo, V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. *Nat. Immunol.* **2005**, *6*, 1245–1252. [[CrossRef](#)]
136. Zhu, C.; Sakuishi, K.; Xiao, S.; Sun, Z.; Zaghoulani, S.; Gu, G.; Wang, C.; Tan, D.J.; Wu, C.; Rangachari, M.; et al. Corrigendum: An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. *Nat. Commun.* **2015**, *6*, 7657. [[CrossRef](#)]
137. van Houtum, E.J.H.; Büll, C.; Cornelissen, L.A.M.; Adema, G.J. Siglec Signaling in the Tumor Microenvironment. *Front. Immunol.* **2021**, *12*, 790317. [[CrossRef](#)]
138. Fraschilla, I.; Pillai, S. Viewing Siglecs through the lens of tumor immunology. *Immunol. Rev.* **2017**, *276*, 178–191. [[CrossRef](#)]
139. Derosiens, N.; Aguilar, W.; DeGaramo, D.A.; Posey, A.D. Sweet Immune Checkpoint Targets to Enhance T Cell Therapy. *J. Immunol.* **2022**, *208*, 278–285. [[CrossRef](#)] [[PubMed](#)]
140. Videla-Richardson, G.A.; Morris-Hanon, O.; Torres, N.I.; Esquivel, M.I.; Vera, M.B.; Ripari, L.B.; Croci, D.O.; Sevlever, G.E.; Rabinovich, G.A. Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma. *Int. J. Mol. Sci.* **2021**, *23*, 316. [[CrossRef](#)] [[PubMed](#)]
141. Girotti, M.R.; Salatino, M.; Dalotto-Moreno, T.; Rabinovich, G.A. Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression. *J. Exp. Med.* **2020**, *217*, e20182041. [[CrossRef](#)]
142. van Vliet, S.J.; Bay, S.; Vuist, I.M.; Kalay, H.; García-Vallejo, J.J.; Leclerc, C.; van Kooyk, Y. MGL signaling augments TLR2-mediated responses for enhanced IL-10 and TNF- α secretion. *J. Leukoc. Biol.* **2013**, *94*, 315–323. [[CrossRef](#)]
143. García-Vallejo, J.J.; Bloem, K.; Knippels, L.M.J.; Garssen, J.; Van Vliet, S.J.; Van Kooyk, Y. The Consequences of Multiple Simultaneous C-Type Lectin-Ligand Interactions: DCIR Alters the Endo-Lysosomal Routing of DC-SIGN. *Front. Immunol.* **2015**, *6*, 87. [[CrossRef](#)]
144. Del Fresno, C.; Iborra, S.; Saz-Leal, P.; Lopez, M.M.; Sancho, D. Flexible Signaling of Myeloid C-Type Lectin Receptors in Immunity and Inflammation. *Front. Immunol.* **2018**, *9*, 804. [[CrossRef](#)]
145. Ostrop, J.; Lang, R. Contact, Collaboration, and Conflict: Signal Integration of Syk-Coupled C-Type Lectin Receptors. *J. Immunol.* **2017**, *198*, 1403–1414. [[CrossRef](#)]
146. Fritz, J.H.; Girardin, S.E.; Fitting, C.; Werts, C.; Mengin-Lecreux, D.; Caroff, M.; Cavaillon, J.-M.; Philpott, D.J.; Adib-Conquy, M. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. *Eur. J. Immunol.* **2005**, *35*, 2459–2470. [[CrossRef](#)]

147. Gringhuis, S.I.; den Dunnen, J.; Litjens, M.; van Het Hof, B.; van Kooyk, Y.; Geijtenbeek, T.B. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB. *Immunity* **2007**, *26*, 605–616. [[CrossRef](#)]
148. O'Neill, L.A.; Sheedy, F.; McCoy, C. MicroRNAs: The fine-tuners of Toll-like receptor signalling. *Nat. Rev. Immunol.* **2011**, *11*, 163–175. [[CrossRef](#)]
149. Bayraktar, R.; Bertilaccio, M.T.S.; Calin, G.A. The Interaction between Two Worlds: MicroRNAs and Toll-Like Receptors. *Front. Immunol.* **2019**, *10*, 1053. [[CrossRef](#)]
150. Ganguly, K.; Kishore, U.; Madan, T. Interplay between C-type lectin receptors and microRNAs in cellular homeostasis and immune response. *FEBS J.* **2021**, *288*, 4210–4229. [[CrossRef](#)]
151. Awuah, D.; Alobaid, M.; Latif, A.; Salazar, F.; Emes, R.D.; Ghaemmaghami, A.M. The Cross-Talk between miR-511-3p and C-Type Lectin Receptors on Dendritic Cells Affects Dendritic Cell Function. *J. Immunol.* **2019**, *203*, 148–157. [[CrossRef](#)]
152. Kalia, N.; Singh, J.; Kaur, M. The role of dectin-1 in health and disease. *Immunobiology* **2021**, *226*, 152071. [[CrossRef](#)]
153. Liu, M.; Luo, F.; Ding, C.; Albeituni, S.; Hu, X.; Ma, Y.; Cai, Y.; McNally, L.; Sanders, M.A.; Jain, D.; et al. Dectin-1 Activation by a Natural Product beta-Glucan Converts Immunosuppressive Macrophages into an M1-like Phenotype. *J. Immunol.* **2015**, *195*, 5055–5065; Correction in *J. Immunol.* **2016**, *196*, 3968. [[CrossRef](#)]
154. Zhao, Y.; Chu, X.; Chen, J.; Wang, Y.; Gao, S.; Jiang, Y.; Zhu, X.; Tan, G.; Zhao, W.; Yi, H.; et al. Dectin-1-activated dendritic cells trigger potent antitumour immunity through the induction of Th9 cells. *Nat. Commun.* **2016**, *7*, 12368. [[CrossRef](#)]
155. Wu, T.-C.; Xu, K.; Banchereau, R.; Marches, F.; I Yu, C.; Martinek, J.; Anguiano, E.; Pedroza-Gonzalez, A.; Snipes, G.J.; O'Shaughnessy, J.; et al. Reprogramming Tumor-Infiltrating Dendritic Cells for CD103+CD8+ Mucosal T-cell Differentiation and Breast Cancer Rejection. *Cancer Immunol. Res.* **2014**, *2*, 487–500. [[CrossRef](#)]
156. Albeituni, S.H.; Ding, C.; Liu, M.; Hu, X.; Luo, F.; Kloecker, G.; Bousamra, M.; Zhang, H.G.; Yan, J. Yeast-Derived Particulate beta-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer. *J. Immunol.* **2016**, *196*, 2167–2180; Correction in *J. Immunol.* **2016**, *196*, 3967. [[CrossRef](#)]
157. Desamero, M.J.; Kakuta, S.; Chambers, J.K.; Uchida, K.; Hachimura, S.; Takamoto, M.; Nakayama, J.; Nakayama, H.; Kyuwa, S. Orally administered brown seaweed-derived beta-glucan effectively restrained development of gastric dysplasia in A4gnt KO mice that spontaneously develop gastric adenocarcinoma. *Int. Immunopharmacol.* **2018**, *60*, 211–220. [[CrossRef](#)] [[PubMed](#)]
158. Xia, Y.; Liu, L.; Bai, Q.; Wang, J.; Xi, W.; Qu, Y.; Xiong, Y.; Long, Q.; Xu, J.; Guo, J. Dectin-1 predicts adverse postoperative prognosis of patients with clear cell renal cell carcinoma. *Sci. Rep.* **2016**, *6*, 32657. [[CrossRef](#)] [[PubMed](#)]
159. Peters, K.; Peters, M. The Role of Lectin Receptors and Their Ligands in Controlling Allergic Inflammation. *Front. Immunol.* **2021**, *12*, 635411. [[CrossRef](#)] [[PubMed](#)]
160. Kimura, Y.; Inoue, A.; Hangai, S.; Saijo, S.; Negishi, H.; Nishio, J.; Yamasaki, S.; Iwakura, Y.; Yanai, H.; Taniguchi, T. The innate immune receptor Dectin-2 mediates the phagocytosis of cancer cells by Kupffer cells for the suppression of liver metastasis. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, 14097–14102. [[CrossRef](#)]
161. Zhu, L.-L.; Zhao, X.-Q.; Jiang, C.; You, Y.; Chen, X.-P.; Jiang, Y.-Y.; Jia, X.-M.; Lin, X. C-Type Lectin Receptors Dectin-3 and Dectin-2 Form a Heterodimeric Pattern-Recognition Receptor for Host Defense against Fungal Infection. *Immunity* **2013**, *39*, 324–334. [[CrossRef](#)]
162. Dalle Vedove, E.; Costabile, G.; Merkel, O.M. Mannose and Mannose-6-Phosphate Receptor-Targeted Drug Delivery Systems and Their Application in Cancer Therapy. *Adv. Healthc. Mater.* **2018**, *7*, e1701398. [[CrossRef](#)]
163. Keler, T.; Ramakrishna, V.; Fanger, M.W. Mannose receptor-targeted vaccines. *Expert Opin. Biol. Ther.* **2004**, *4*, 1953–1962. [[CrossRef](#)]
164. Fiani, M.L.; Barreca, V.; Sargiacomo, M.; Ferrantelli, F.; Manfredi, F.; Federico, M. Exploiting Manipulated Small Extracellular Vesicles to Subvert Immunosuppression at the Tumor Microenvironment Through Mannose Receptor/CD206 Targeting. *Int. J. Mol. Sci.* **2020**, *21*, 6318. [[CrossRef](#)]
165. Harris, N.; Super, M.; Rits, M.; Chang, G.; Ezekowitz, R.A. Characterization of the murine macrophage mannose receptor: Demonstration that the downregulation of receptor expression mediated by interferon-gamma occurs at the level of transcription. *Blood* **1992**, *80*, 2363–2373. [[CrossRef](#)]
166. Garcia-Vallejo, J.J.; Ilarregui, J.M.; Kalay, H.; Chamorro, S.; Koning, N.; Unger, W.W.; Ambrosini, M.; Montserrat, V.; Fernandes, R.J.; Bruijns, S.C.M.; et al. CNS myelin induces regulatory functions of DC-SIGN-expressing, antigen-presenting cells via cognate interaction with MOG. *J. Exp. Med.* **2014**, *211*, 1465–1483. [[CrossRef](#)]
167. Appelmelk, B.J.; van Die, I.; van Vliet, S.J.; Vandenbroucke-Grauls, C.M.; Geijtenbeek, T.B.; van Kooyk, Y. Cutting edge: Carbohydrate profiling identifies new pathogens that interact with dendritic cell-specific ICAM-3-grabbing nonintegrin on dendritic cells. *J. Immunol.* **2003**, *170*, 1635–1639. [[CrossRef](#)] [[PubMed](#)]
168. Geijtenbeek, T.B.H.; Gringhuis, S.I. Signalling through C-type lectin receptors: Shaping immune responses. *Nat. Rev. Immunol.* **2009**, *9*, 465–479. [[CrossRef](#)] [[PubMed](#)]
169. Wang, S.-F.; Huang, J.C.; Lee, Y.-M.; Liu, S.-J.; Chan, Y.-J.; Chau, Y.-P.; Chong, P.; Chen, Y.M.A. DC-SIGN mediates avian H5N1 influenza virus infection in cis and in trans. *Biochem. Biophys. Res. Commun.* **2008**, *373*, 561–566. [[CrossRef](#)] [[PubMed](#)]
170. Rappocciolo, G.; Hensler, H.R.; Jais, M.; Reinhart, T.A.; Pegu, A.; Jenkins, F.J.; Rinaldo, C.R. Human Herpesvirus 8 Infects and Replicates in Primary Cultures of Activated B Lymphocytes through DC-SIGN. *J. Virol.* **2008**, *82*, 4793–4806. [[CrossRef](#)] [[PubMed](#)]

171. Rodriguez, E.; Boelaars, K.; Brown, K.; Madunić, K.; van Ee, T.; Dijk, F.; Verheij, J.; Li, R.J.E.; Schetters, S.T.T.; Meijer, L.L.; et al. Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits. *Commun. Biol.* **2022**, *5*, 41. [[CrossRef](#)]
172. Matsumoto, M.; Tanaka, T.; Kaisho, T.; Sanjo, H.; Copeland, N.G.; Gilbert, D.J.; Jenkins, N.A.; Akira, S. A novel LPS-inducible C-type lectin is a transcriptional target of NF-IL6 in macrophages. *J. Immunol.* **1999**, *163*, 5039–5048.
173. Ishikawa, E.; Ishikawa, T.; Morita, Y.S.; Toyonaga, K.; Yamada, H.; Takeuchi, O.; Kinoshita, T.; Akira, S.; Yoshikai, Y.; Yamasaki, S. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. *J. Exp. Med.* **2009**, *206*, 2879–2888. [[CrossRef](#)]
174. Nagata, M.; Izumi, Y.; Ishikawa, E.; Kiyotake, R.; Doi, R.; Iwai, S.; Omahdi, Z.; Yamaji, T.; Miyamoto, T.; Bamba, T.; et al. Intracellular metabolite beta-glucosylceramide is an endogenous Mincle ligand possessing immunostimulatory activity. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E3285–E3294. [[CrossRef](#)]
175. Decout, A.; Silva-Gomes, S.; Drocourt, D.; Barbe, S.; André, I.; Cueto, F.J.; Lioux, T.; Sancho, D.; Pérouzel, E.; Vercellone, A.; et al. Rational design of adjuvants targeting the C-type lectin Mincle. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 2675–2680. [[CrossRef](#)]
176. Yamasaki, S.; Ishikawa, E.; Sakuma, M.; Hara, H.; Ogata, K.; Saito, T. Mincle is an ITAM-coupled activating receptor that senses damaged cells. *Nat. Immunol.* **2008**, *9*, 1179–1188. [[CrossRef](#)]
177. Strasser, D.; Neumann, K.; Bergmann, H.; Marakalala, M.J.; Guler, R.; Rojowska, A.; Hopfner, K.P.; Brombacher, F.; Urlaub, H.; Baier, G.; et al. Syk kinase-coupled C-type lectin receptors engage protein kinase C-delta to elicit Card9 adaptor-mediated innate immunity. *Immunity* **2012**, *36*, 32–42. [[CrossRef](#)]
178. Roth, S.; Bergmann, H.; Jaeger, M.; Yeroslaviz, A.; Neumann, K.; Koenig, P.-A.; da Costa, C.P.; Vanes, L.; Kumar, V.; Johnson, M.; et al. Vav Proteins Are Key Regulators of Card9 Signaling for Innate Antifungal Immunity. *Cell Rep.* **2016**, *17*, 2572–2583. [[CrossRef](#)]
179. Seifert, L.; Werba, G.; Tiwari, S.; Ly, N.N.G.; Alothman, S.; Alqunaibit, D.; Avanzi, A.; Barilla, R.; Daley, D.; Greco, S.H.; et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. *Nature* **2016**, *532*, 245–249, Correction in *Nature* **2021**, *591*, E28. <https://doi.org/10.1038/s41586-021-03322-8>. [[CrossRef](#)]
180. Roperto, S.; Russo, V.; Esposito, I.; Ceccarelli, D.M.; Paciello, O.; Avallone, L.; Capparelli, R.; Roperto, F. Mincle, an Innate Immune Receptor, Is Expressed in Urothelial Cancer Cells of Papillomavirus-Associated Urothelial Tumors of Cattle. *PLoS ONE* **2015**, *10*, e0141624. [[CrossRef](#)]
181. Li, C.; Xue, V.W.; Wang, Q.M.; Lian, G.Y.; Huang, X.R.; Lee, T.L.; To, K.F.; Tang, P.M.K.; Lan, H.Y. The Mincle/Syk/NF-kappaB Signaling Circuit Is Essential for Maintaining the Protumoral Activities of Tumor-Associated Macrophages. *Cancer Immunol. Res.* **2020**, *8*, 1004–1017. [[CrossRef](#)] [[PubMed](#)]
182. Bates, E.; Fournier, N.; Garcia, E.; Valladeau, J.; Durand, I.; Pin, J.J.; Zurawski, S.M.; Patel, S.; Abrams, J.S.; Lebecque, S.; et al. APCs express DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif. *J. Immunol.* **1999**, *163*, 1973–1983.
183. Bloem, K.; Vuist, I.M.; Berk, M.V.D.; Klaver, E.J.; van Die, I.; Knippels, L.M.; Garssen, J.; García-Vallejo, J.J.; van Vliet, S.J.; van Kooyk, Y. DCIR interacts with ligands from both endogenous and pathogenic origin. *Immunol. Lett.* **2014**, *158*, 33–41. [[CrossRef](#)]
184. Kanazawa, N.; Okazaki, T.; Nishimura, H.; Tashiro, K.; Inaba, K.; Miyachi, Y. DCIR Acts as an Inhibitory Receptor Depending on its Immunoreceptor Tyrosine-Based Inhibitory Motif11A preliminary report of these results was presented by the first author at the 61st annual meeting of SID in Chicago in the session “General Immunology”. *J. Investig. Dermatol.* **2002**, *118*, 261–266. [[CrossRef](#)]
185. Meyer-Wentrup, F.; Cambi, A.; Joosten, B.; Looman, M.W.; De Vries, I.J.M.; Figdor, C.G.; Adema, G.J. DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production. *J. Leukoc. Biol.* **2009**, *85*, 518–525. [[CrossRef](#)]
186. Meyer-Wentrup, F.; Benitez-Ribas, D.; Tacke, P.J.; Punt, C.J.A.; Figdor, C.G.; de Vries, I.J.M.; Adema, G.J. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN- α production. *Blood* **2008**, *111*, 4245–4253. [[CrossRef](#)] [[PubMed](#)]
187. Nagae, M.; Ikeda, A.; Hanashima, S.; Kojima, T.; Matsumoto, N.; Yamamoto, K.; Yamaguchi, Y. Crystal structure of human dendritic cell inhibitory receptor C-type lectin domain reveals the binding mode with N-glycan. *FEBS Lett.* **2016**, *590*, 1280–1288. [[CrossRef](#)] [[PubMed](#)]
188. McGreal, E.P.; Miller, J.L.; Gordon, S. Ligand recognition by antigen-presenting cell C-type lectin receptors. *Curr. Opin. Immunol.* **2005**, *17*, 18–24. [[CrossRef](#)] [[PubMed](#)]
189. Denda-Nagai, K.; Kubota, N.; Tsuiji, M.; Kamata, M.; Irimura, T. Macrophage C-type lectin on bone marrow-derived immature dendritic cells is involved in the internalization of glycosylated antigens. *Glycobiology* **2002**, *12*, 443–450. [[CrossRef](#)] [[PubMed](#)]
190. Singh, S.K.; Streng-Ouwehand, I.; Litjens, M.; Weelij, D.R.; García-Vallejo, J.J.; van Vliet, S.J.; Saeland, E.; van Kooyk, Y. Characterization of murine MGL1 and MGL2 C-type lectins: Distinct glycan specificities and tumor binding properties. *Mol. Immunol.* **2009**, *46*, 1240–1249. [[CrossRef](#)] [[PubMed](#)]
191. Higashi, N.; Fujioka, K.; Denda-Nagai, K.; Hashimoto, S.-I.; Nagai, S.; Sato, T.; Fujita, Y.; Morikawa, A.; Tsuiji, M.; Miyata-Takeuchi, M.; et al. The Macrophage C-type Lectin Specific for Galactose/N-Acetylgalactosamine Is an Endocytic Receptor Expressed on Monocyte-derived Immature Dendritic Cells. *J. Biol. Chem.* **2002**, *277*, 20686–20693. [[CrossRef](#)]

192. van Vliet, S.J.; van Liempt, E.; Geijtenbeek, T.B.; van Kooyk, Y. Differential regulation of C-type lectin expression on tolerogenic dendritic cell subsets. *Immunobiology* **2006**, *211*, 577–585. [[CrossRef](#)]
193. Kumamoto, Y.; Linehan, M.; Weinstein, J.S.; Laidlaw, B.J.; Craft, J.E.; Iwasaki, A. CD301b+ Dermal Dendritic Cells Drive T Helper 2 Cell-Mediated Immunity. *Immunity* **2013**, *39*, 733–743. [[CrossRef](#)]
194. Freire, T.; Zhang, X.; Deriaud, E.; Ganneau, C.; Vichier-Guerre, S.; Azria, E.; Launay, O.; Lo-Man, R.; Bay, S.; Leclerc, C. Glycosidic Tn-based vaccines targeting dermal dendritic cells favor germinal center B-cell development and potent antibody response in the absence of adjuvant. *Blood* **2010**, *116*, 3526–3536. [[CrossRef](#)]
195. van Vliet, S.J.; Gringhuis, S.I.; Geijtenbeek, T.B.; van Kooyk, Y. Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. *Nat. Immunol.* **2006**, *7*, 1200–1208. [[CrossRef](#)]
196. Terävä, J.; Tiainen, L.; Lamminmäki, U.; Kellokumpu-Lehtinen, P.-L.; Pettersson, K.; Gidwani, K. Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma. *PLoS ONE* **2019**, *14*, e0219480. [[CrossRef](#)] [[PubMed](#)]
197. Manojlovic, N.; Savic, G.; Nikolic, B.; Rancic, N. Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy. *World J. Clin. Cases* **2022**, *10*, 899–918. [[CrossRef](#)]
198. Thomakos, N.; Rodolakis, A.; Zagouri, F.; Zacharakis, D.; Sotiropoulou, M.; Akrivos, N.; Haidopoulos, D.; Papadimitriou, C.A.; Dimopoulos, M.A.; Antsaklis, A. Serum CA 125, CA 15-3, CEA, and CA 19-9: A prognostic factor for uterine carcinosarcomas? *Arch. Gynecol. Obstet.* **2013**, *287*, 97–102. [[CrossRef](#)] [[PubMed](#)]
199. Napoletano, C.; Steentoff, C.; Battisti, F.; Ye, Z.; Rahimi, H.; Zizzari, I.G.; Dionisi, M.; Cerbelli, B.; Tomao, F.; French, D.; et al. Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-type Lectin (MGL). *Cancers* **2020**, *12*, 2841. [[CrossRef](#)] [[PubMed](#)]
200. Lenos, K.; Goos, J.A.C.M.; Vuist, I.M.; Den Uil, S.H.; Diemen, P.M.D.-V.; Belt, E.J.T.; Stockmann, H.B.A.C.; Bril, H.; De Wit, M.; Carvalho, B.; et al. MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients. *Oncotarget* **2015**, *6*, 26278–26290. [[CrossRef](#)]
201. Pirro, M.; Rombouts, Y.; Stella, A.; Neyrolles, O.; Burlet-Schiltz, O.; van Vliet, S.J.; de Ru, A.H.; Mohammed, Y.; Wuhrer, M.; van Veelen, P.A.; et al. Characterization of Macrophage Galactose-type Lectin (MGL) ligands in colorectal cancer cell lines. *Biochim. Biophys. Acta (BBA) Gen. Subj.* **2020**, *1864*, 129513. [[CrossRef](#)]
202. Sahasrabudhe, N.M.; Lenos, K.; van der Horst, J.C.; Rodríguez, E.; van Vliet, S.J. Oncogenic BRAFV600E drives expression of MGL ligands in the colorectal cancer cell line HT29 through N-acetylgalactosamine-transferase 3. *Biol. Chem.* **2018**, *399*, 649–659. [[CrossRef](#)]
203. Beatson, R.; Maurstad, G.; Picco, G.; Arulappu, A.; Coleman, J.; Wandell, H.H.; Clausen, H.; Mandel, U.; Taylor-Papadimitriou, J.; Sletmoen, M.; et al. The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL. *PLoS ONE* **2015**, *10*, e0125994. [[CrossRef](#)]
204. Saeland, E.; Belo, A.I.; Mongera, S.; van Die, I.; Meijer, G.A.; van Kooyk, Y. Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients. *Int. J. Cancer* **2012**, *131*, 117–128. [[CrossRef](#)]
205. Saeland, E.; van Vliet, S.J.; Bäckström, M.; van den Berg, V.C.M.; Geijtenbeek, T.B.H.; Meijer, G.A.; van Kooyk, Y. The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. *Cancer Immunol. Immunother.* **2007**, *56*, 1225–1236. [[CrossRef](#)]
206. Bulteau, F.; Thépaut, M.; Henry, M.; Hurbin, A.; Vanwonderghem, L.; Vivès, C.; Le Roy, A.; Ebel, C.; Renaudet, O.; Fieschi, F.; et al. Targeting Tn-Antigen-Positive Human Tumors with a Recombinant Human Macrophage Galactose C-Type Lectin. *Mol. Pharm.* **2022**, *19*, 235–245. [[CrossRef](#)]
207. Dusoswa, S.A.; Verhoeff, J.; Abels, E.; Méndez-Huergo, S.P.; Croci, D.O.; Kuijper, L.H.; de Miguel, E.; Wouters, V.M.C.J.; Best, M.G.; Rodriguez, E.; et al. Glioblastomas exploit truncated O-linked glycans for local and distant immune modulation via the macrophage galactose-type lectin. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 3693–3703. [[CrossRef](#)]
208. Festari, M.F.; da Costa, V.; Rodríguez-Zraquia, S.A.; Costa, M.; Landeira, M.; Lores, P.; Solari-Saquieres, P.; Kramer, M.G.; Freire, T. The tumour-associated Tn antigen fosters lung metastasis and recruitment of regulatory T cells in triple negative breast cancer. *Glycobiology* **2021**. [[CrossRef](#)] [[PubMed](#)]
209. Xie, F.; Zhou, X.; Fang, M.; Li, H.; Su, P.; Tu, Y.; Zhang, L.; Zhou, F. Extracellular Vesicles in Cancer Immune Microenvironment and Cancer Immunotherapy. *Adv. Sci.* **2019**, *6*, 1901779. [[CrossRef](#)]
210. Barros, F.M.; Carneiro, F.; Machado, J.C.; Melo, S.A. Exosomes and Immune Response in Cancer: Friends or Foes? *Front. Immunol.* **2018**, *9*, 730. [[CrossRef](#)]
211. Chang, C.-H.; Pauklin, S. Extracellular vesicles in pancreatic cancer progression and therapies. *Cell Death Dis.* **2021**, *12*, 973. [[CrossRef](#)]
212. Chang, W.-H.; Cerione, R.A.; Antonyak, M.A. Extracellular Vesicles and Their Roles in Cancer Progression. In *Cancer Cell Signaling; Humana*: New York, NY, USA, 2021; Volume 2174, pp. 143–170. [[CrossRef](#)]
213. Martins, M.; Ramos, C.C.; Freitas, D.; Reis, C.A. Glycosylation of Cancer Extracellular Vesicles: Capture Strategies, Functional Roles and Potential Clinical Applications. *Cells* **2021**, *10*, 109. [[CrossRef](#)]
214. Costa, J.; Gatermann, M.; Nimtz, M.; Kandzia, S.; Glatzel, M.; Conradt, H.S. N-Glycosylation of Extracellular Vesicles from HEK-293 and Glioma Cell Lines. *Anal. Chem.* **2018**, *90*, 7871–7879. [[CrossRef](#)]

215. Gomes, J.; Gomes-Alves, P.; Carvalho, S.B.; Peixoto, C.; Alves, P.M.; Altevogt, P.; Costa, J. Extracellular Vesicles from Ovarian Carcinoma Cells Display Specific Glycosignatures. *Biomolecules* **2015**, *5*, 1741–1761. [[CrossRef](#)]
216. Freitas, D.; Balmaña, M.; Poças, J.; Campos, D.; Osório, H.; Konstantinidi, A.; Vakhrushev, S.Y.; Magalhães, A.; Reis, C.A. Different isolation approaches lead to diverse glycosylated extracellular vesicle populations. *J. Extracell. Vesicles* **2019**, *8*, 1621131. [[CrossRef](#)]
217. Batista, B.S.; Eng, W.S.; Pilobello, K.T.; Hendricks-Muñoz, K.D.; Mahal, L.K. Identification of a Conserved Glycan Signature for Microvesicles. *J. Proteome Res.* **2011**, *10*, 4624–4633. [[CrossRef](#)] [[PubMed](#)]
218. Saunderson, S.; Dunn, A.C.; Crocker, P.; McLellan, A.D. CD169 mediates the capture of exosomes in spleen and lymph node. *Blood* **2014**, *123*, 208–216. [[CrossRef](#)] [[PubMed](#)]
219. Williams, C.; Pazos, R.; Royo, F.; González, E.; Roura-Ferrer, M.; Martinez, A.; Gamiz, J.; Reichardt, N.-C.; Falcón-Pérez, J.M. Assessing the role of surface glycans of extracellular vesicles on cellular uptake. *Sci. Rep.* **2019**, *9*, 11920. [[CrossRef](#)]
220. Liang, Y.; Eng, W.S.; Colquhoun, D.R.; Dinglasan, R.R.; Graham, D.R.; Mahal, L.K. Complex N-Linked Glycans Serve as a Determinant for Exosome/Microvesicle Cargo Recruitment. *J. Biol. Chem.* **2014**, *289*, 32526–32537. [[CrossRef](#)]
221. Hara-Kuge, S.; Ohkura, T.; Ideo, H.; Shimada, O.; Atsumi, S.; Yamashita, K. Involvement of VIP36 in Intracellular Transport and Secretion of Glycoproteins in Polarized Madin-Darby Canine Kidney (MDCK) Cells. *J. Biol. Chem.* **2002**, *277*, 16332–16339. [[CrossRef](#)]
222. Teixeira, F.C.O.B.; Götte, M. Involvement of Syndecan-1 and Heparanase in Cancer and Inflammation. *Heparanase* **2020**, *1221*, 97–135. [[CrossRef](#)]
223. Tan, Z.; Cao, L.; Wu, Y.; Wang, B.; Song, Z.; Yang, J.; Cheng, L.; Yang, X.; Zhou, X.; Dai, Z.; et al. Bisecting GlcNAc modification diminishes the pro-metastatic functions of small extracellular vesicles from breast cancer cells. *J. Extracell. Vesicles* **2020**, *10*, e12005. [[CrossRef](#)]
224. Cao, L.; Wu, Y.; Wang, X.; Li, X.; Tan, Z.; Guan, F. Role of Site-Specific Glycosylation in the I-Like Domain of Integrin beta1 in Small Extracellular Vesicle-Mediated Malignant Behavior and FAK Activation. *Int. J. Mol. Sci.* **2021**, *22*, 1770. [[CrossRef](#)]
225. Clark, D.J.; Schnaubelt, M.; Hoti, N.; Hu, Y.; Zhou, Y.; Gooya, M.; Zhang, H. Impact of Increased FUT8 Expression on the Extracellular Vesicle Proteome in Prostate Cancer Cells. *J. Proteome Res.* **2020**, *19*, 2195–2205. [[CrossRef](#)]
226. Gao, T.; Wen, T.; Ge, Y.; Liu, J.; Yang, L.; Jiang, Y.; Dong, X.; Liu, H.; Yao, J.; An, G. Disruption of Core 1-mediated O-glycosylation oppositely regulates CD44 expression in human colon cancer cells and tumor-derived exosomes. *Biochem. Biophys. Res. Commun.* **2020**, *521*, 514–520. [[CrossRef](#)]
227. Terävä, J.; Verhassel, A.; Botti, O.; Islam, K.; Leivo, J.; Wittfooth, S.; Härkönen, P.; Pettersson, K.; Gidwani, K. Primary breast cancer biomarkers based on glycosylation and extracellular vesicles detected from human serum. *Cancer Rep.* **2021**, e1540. [[CrossRef](#)] [[PubMed](#)]
228. van Dinther, D.; Stolk, D.A.; van de Ven, R.; van Kooyk, Y.; de Gruijl, T.D.; den Haan, J.M. Targeting C-type lectin receptors: A high-carbohydrate diet for dendritic cells to improve cancer vaccines. *J. Leukoc. Biol.* **2017**, *102*, 1017–1034. [[CrossRef](#)] [[PubMed](#)]
229. Li, R.E.; Hogervorst, T.; Achilli, S.; Bruijns, S.C.; Arnoldus, T.; Vivès, C.; Wong, C.C.; Thépaut, M.; Meeuwenoord, N.J.; Elst, H.V.D.; et al. Systematic Dual Targeting of Dendritic Cell C-Type Lectin Receptor DC-SIGN and TLR7 Using a Trifunctional Mannosylated Antigen. *Front. Chem.* **2019**, *7*, 650. [[CrossRef](#)] [[PubMed](#)]
230. Lo-Man, R.; Hsi, L.C.; Xi, X.; Lotan, R.; Shureiqi, I.; Lippman, S.M. A Fully Synthetic Therapeutic Vaccine Candidate Targeting Carcinoma-Associated Tn Carbohydrate Antigen Induces Tumor-Specific Antibodies in Nonhuman Primates. *Cancer Res.* **2004**, *64*, 4987–4994. [[CrossRef](#)]
231. Cardenas, F.I.; Mauguen, A.; Cheung, I.Y.; Kramer, K.; Kushner, B.H.; Ragupathi, G.; Cheung, N.V.; Modak, S. Phase I Trial of Oral Yeast-Derived beta-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. *Cancers* **2021**, *13*, 6265. [[CrossRef](#)]
232. Cheung, I.Y.; Cheung, N.K.V.; Modak, S.; Mauguen, A.; Feng, Y.; Basu, E.; Roberts, S.S.; Ragupathi, G.; Kushner, B.H. Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients with High-Risk Neuroblastoma with Prior Disease Progression. *J. Clin. Oncol.* **2021**, *39*, 215–226. [[CrossRef](#)]
233. Bonifaz, L.C.; Bonnyay, D.P.; Charalambous, A.; Darguste, D.I.; Fujii, S.-I.; Soares, H.; Brimnes, M.K.; Moltedo, B.; Moran, T.M.; Steinman, R.M. In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination. *J. Exp. Med.* **2004**, *199*, 815–824. [[CrossRef](#)]
234. Bonifaz, L.; Bonnyay, D.; Mahnke, K.; Rivera, M.; Nussenzweig, M.C.; Steinman, R.M. Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance. *J. Exp. Med.* **2002**, *196*, 1627–1638. [[CrossRef](#)]
235. Amon, R.; Rosenfeld, R.; Perlmutter, S.; Grant, O.C.; Yehuda, S.; Borenstein-Katz, A.; Alcalay, R.; Marshanski, T.; Yu, H.; Diskin, R.; et al. Directed Evolution of Therapeutic Antibodies Targeting Glycosylation in Cancer. *Cancers* **2020**, *12*, 2824. [[CrossRef](#)]
236. Arigita, C.; Bevaart, L.; Everse, L.A.; Koning, G.A.; Hennink, W.E.; Crommelin, D.J.A.; van de Winkel, J.G.J.; van Vugt, M.J.; Kersten, G.F.A.; Jiskoot, W. Liposomal Meningococcal B Vaccination: Role of Dendritic Cell Targeting in the Development of a Protective Immune Response. *Infect. Immun.* **2003**, *71*, 5210–5218. [[CrossRef](#)]
237. Copland, M.J.; Baird, M.A.; Rades, T.; McKenzie, J.L.; Becker, B.; Reck, F.; Tyler, P.C.; Davies, N.M. Liposomal delivery of antigen to human dendritic cells. *Vaccine* **2003**, *21*, 883–890. [[CrossRef](#)]

238. Sheng, K.C.; Kalkanidis, M.; Pouniotis, D.S.; Esparon, S.; Tang, C.K.; Apostolopoulos, V.; Pietersz, G.A. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. *Eur. J. Immunol.* **2008**, *38*, 424–436. [[CrossRef](#)]
239. Hamdy, S.; Haddadi, A.; Shayeganpour, A.; Samuel, J.; Lavasanifar, A. Activation of Antigen-Specific T Cell-Responses by Mannan-Decorated PLGA Nanoparticles. *Pharm. Res.* **2011**, *28*, 2288–2301. [[CrossRef](#)]
240. Joshi, M.; Unger, W.J.; Storm, G.; van Kooyk, Y.; Mastrobattista, E. Targeting tumor antigens to dendritic cells using particulate carriers. *J. Control. Release* **2012**, *161*, 25–37. [[CrossRef](#)]
241. Karanikas, V.; Hwang, L.A.; Pearson, J.; Ong, C.S.; Apostolopoulos, V.; Vaughan, H.; Xing, P.X.; Jamieson, G.; Pietersz, G.; Tait, B.; et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. *J. Clin. Investig.* **1997**, *100*, 2783–2792. [[CrossRef](#)]
242. Apostolopoulos, V.; Karanikas, V.; Haurum, J.S.; McKenzie, I.F. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. *J. Immunol.* **1997**, *159*, 5211–5218.
243. Kaps, L.; Leber, N.; Klefenz, A.; Choteschovsky, N.; Zentel, R.; Nuhn, L.; Schuppan, D. In Vivo siRNA Delivery to Immunosuppressive Liver Macrophages by α -Mannosyl-Functionalized Cationic Nanohydrogel Particles. *Cells* **2020**, *9*, 1905. [[CrossRef](#)]
244. Moku, G.; Vangala, S.; Gulla, S.K.; Yakati, V. In vivo Targeting of DNA Vaccines to Dendritic Cells via the Mannose Receptor Induces Long-Lasting Immunity against Melanoma. *ChemBioChem* **2021**, *22*, 523–531. [[CrossRef](#)]
245. Dou, W.-T.; Xu, F.; Xu, C.-X.; Gao, J.; Ru, H.-B.; Luan, X.; Zhang, J.; Zhu, L.; Sedgwick, A.C.; Chen, G.-R.; et al. Graphene nanoribbon-based supramolecular ensembles with dual-receptor targeting function for targeted photothermal tumor therapy. *Chem. Sci.* **2021**, *12*, 11089–11097. [[CrossRef](#)]
246. Figueiredo, P.; Lepland, A.; Scodeller, P.; Fontana, F.; Torrieri, G.; Tiboni, M.; Shahbazi, M.; Casettari, L.; Kostianen, M.A.; Hirvonen, J.; et al. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy. *Acta Biomater.* **2021**, *133*, 231–243. [[CrossRef](#)]
247. Hu, J.; Wei, P.; Seeberger, P.H.; Yin, J. Mannose-Functionalized Nanoscaffolds for Targeted Delivery in Biomedical Applications. *Chem. Asian J.* **2018**, *13*, 3448–3459. [[CrossRef](#)] [[PubMed](#)]
248. Buskas, T.; Ingale, S.; Boons, G.-J. Towards a Fully Synthetic Carbohydrate-Based Anticancer Vaccine: Synthesis and Immunological Evaluation of a Lipidated Glycopeptide Containing the Tumor-Associated Tn Antigen. *Angew. Chem. Int. Ed.* **2005**, *44*, 5985–5988. [[CrossRef](#)] [[PubMed](#)]
249. van Kooyk, Y.; Unger, W.W.; Fehres, C.M.; Kalay, H.; García-Vallejo, J.J. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation. *Mol. Immunol.* **2013**, *55*, 143–145. [[CrossRef](#)] [[PubMed](#)]
250. García-Vallejo, J.J.; Unger, W.W.J.; Kalay, H.; van Kooyk, Y. Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines. *OncoImmunology* **2013**, *2*, e23040. [[CrossRef](#)] [[PubMed](#)]
251. Fehres, C.M.; Kalay, H.; Bruijns, S.C.; Musaafir, S.A.; Ambrosini, M.; van Bloois, L.; van Vliet, S.J.; Storm, G.; Garcia-Vallejo, J.J.; van Kooyk, Y. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens. *J. Control. Release* **2015**, *203*, 67–76. [[CrossRef](#)] [[PubMed](#)]
252. Berzi, A.; Ordanini, S.; Joosten, B.; Trabattini, D.; Cambi, A.; Bernardi, A.; Clerici, M. Pseudo-Mannosylated DC-SIGN Ligands As Immunomodulants. *Sci. Rep.* **2016**, *6*, 35373. [[CrossRef](#)] [[PubMed](#)]
253. Le Moignic, A.; Malard, V.; Benvegna, T.; Lemiègre, L.; Berchel, M.; Jaffrès, P.-A.; Baillou, C.; Delost, M.; Macedo, R.; Rochefort, J.; et al. Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells. *J. Control. Release* **2018**, *278*, 110–121. [[CrossRef](#)]
254. Silva, J.M.; Zupancic, E.; Vandermeulen, G.; Oliveira, V.G.; Salgado, A.; Videira, M.; Gaspar, M.; Graca, L.; Prét, V.; Florindo, H.F. In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model. *J. Control. Release* **2015**, *198*, 91–103. [[CrossRef](#)]
255. Horrevorts, S.K.; Stolk, D.A.; Van De Ven, R.; Hulst, M.; Hof, B.V.H.; Duinkerken, S.; Heineke, M.H.; Ma, W.; Dusoswa, S.A.; Nieuwland, R.; et al. Glycan-Modified Melanoma-Derived Apoptotic Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination. *Cancers* **2019**, *11*, 1266. [[CrossRef](#)]
256. Carter, R.W.; Thompson, C.; Reid, D.M.; Wong, S.Y.C.; Tough, D.F. Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. *J. Immunol.* **2006**, *177*, 2276–2284. [[CrossRef](#)]
257. Ni, L.; Gayet, I.; Zurawski, S.; Duluc, D.; Flamar, A.-L.; Li, X.-H.; O’Bar, A.; Clayton, S.; Palucka, A.K.; Zurawski, G.; et al. Concomitant Activation and Antigen Uptake via Human Dectin-1 Results in Potent Antigen-Specific CD8+ T Cell Responses. *J. Immunol.* **2010**, *185*, 3504–3513. [[CrossRef](#)] [[PubMed](#)]
258. Donadei, A.; Gallorini, S.; Berti, F.; O’Hagan, D.T.; Adamo, R.; Baudner, B.C. Rational Design of Adjuvant for Skin Delivery: Conjugation of Synthetic beta-Glucan Dectin-1 Agonist to Protein Antigen. *Mol. Pharm.* **2015**, *12*, 1662–1672. [[CrossRef](#)] [[PubMed](#)]
259. Lipinski, T.; Fiteh, A.; Pierre, J.S.; Ostergaard, H.L.; Bundle, D.R.; Touret, N. Enhanced immunogenicity of a tricomponent mannan tetanus toxoid conjugate vaccine targeted to dendritic cells via Dectin-1 by incorporating beta-glucan. *J. Immunol.* **2013**, *190*, 4116–4128. [[CrossRef](#)]
260. Xie, J.; Guo, L.; Ruan, Y.; Zhu, H.; Wang, L.; Zhou, L.; Yun, X.; Gu, J. Laminarin-mediated targeting to Dectin-1 enhances antigen-specific immune responses. *Biochem. Biophys. Res. Commun.* **2010**, *391*, 958–962. [[CrossRef](#)] [[PubMed](#)]
261. Trabbic, K.R.; Kleski, K.A.; Barchi, J.J., Jr. Stable Gold-Nanoparticle-Based Vaccine for the Targeted Delivery of Tumor-Associated Glycopeptide Antigens. *ACS Bio Med. Chem Au* **2021**, *1*, 31–43. [[CrossRef](#)] [[PubMed](#)]

262. Zeeshan, M.; Ali, H.; Ain, Q.U.; Mukhtar, M.; Gul, R.; Sarwar, A.; Khan, S. A holistic QBD approach to design galactose conjugated PLGA polymer and nanoparticles to catch macrophages during intestinal inflammation. *Mater. Sci. Eng. C* **2021**, *126*, 112183. [[CrossRef](#)] [[PubMed](#)]
263. Eggink, L.L.; Roby, K.F.; Cote, R.; Hooper, J.K. An Innovative Immunotherapeutic Strategy for Ovarian Cancer: CLEC10A and Glycomimetic Peptides. *J. Immunother. Cancer* **2018**, *6*, 28. [[CrossRef](#)]
264. Lehmann, C.H.K.; Heger, L.; Heidkamp, G.F.; Baranska, A.; Luehr, J.J.; Hoffmann, A.; Dudziak, D. Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies. *Vaccines* **2016**, *4*, 8. [[CrossRef](#)]
265. Chappell, C.P.; Draves, K.E.; Giltiay, N.V.; Clark, E.A. Extrafollicular B cell activation by marginal zone dendritic cells drives T cell-dependent antibody responses. *J. Exp. Med.* **2012**, *209*, 1825–1840. [[CrossRef](#)]
266. Yu, A.L.; Gilman, A.L.; Ozkaynak, M.F.; Naranjo, A.; Diccianni, M.B.; Gan, J.; Hank, J.A.; Batova, A.; London, W.B.; Tenney, S.C.; et al. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. *Clin. Cancer Res.* **2021**, *27*, 2179–2189. [[CrossRef](#)]
267. Ploessl, C.; Pan, A.; Maples, K.T.; Lowe, D.K. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma. *Ann. Pharmacother.* **2016**, *50*, 416–422. [[CrossRef](#)] [[PubMed](#)]
268. Mueller, B.M.; Romerdahl, C.A.; Gillies, S.D.; Reisfeld, R.A. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. *J. Immunol.* **1990**, *144*, 1382–1386. [[PubMed](#)]
269. Yu, A.L.; Gilman, A.L.; Ozkaynak, M.F.; London, W.B.; Kreissman, S.G.; Chen, H.X.; Smith, M.; Anderson, B.; Villablanca, J.G.; Matthay, K.K.; et al. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. *N. Engl. J. Med.* **2010**, *363*, 1324–1334. [[CrossRef](#)] [[PubMed](#)]
270. Riley, R.S.; June, C.H.; Langer, R.; Mitchell, M.J. Delivery technologies for cancer immunotherapy. *Nat. Rev. Drug Discov.* **2019**, *18*, 175–196. [[CrossRef](#)]
271. Abrantes, R.; Duarte, H.O.; Gomes, C.; Wälchli, S.; Reis, C.A. CAR-Ts: New perspectives in cancer therapy. *FEBS Lett.* **2022**, *596*, 403–416. [[CrossRef](#)]
272. Craddock, J.A.; Lu, A.; Bear, A.; Pule, M.; Brenner, M.K.; Rooney, C.M.; Foster, A.E. Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b. *J. Immunother.* **2010**, *33*, 780–788. [[CrossRef](#)]
273. Bocca, P.; Di Carlo, E.; Caruana, I.; Emionite, L.; Cilli, M.; De Angelis, B.; Quintarelli, C.; Pezzolo, A.; Raffaghello, L.; Morandi, F.; et al. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model. *OncolImmunology* **2017**, *7*, e1378843. [[CrossRef](#)]
274. Gargett, T.; Yu, W.; Dotti, G.; Yvon, E.S.; Christo, S.N.; Hayball, J.; Lewis, I.D.; Brenner, M.K.; Brown, M. GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. *Mol. Ther.* **2016**, *24*, 1135–1149. [[CrossRef](#)]
275. Rashidijahanabad, Z.; Huang, X. Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy. *Semin. Immunol.* **2020**, *47*, 101390. [[CrossRef](#)]
276. Wilkie, S.; Picco, G.; Foster, J.; Davies, D.M.; Julien, S.; Cooper, L.; Arif, S.; Mather, S.J.; Taylor-Papadimitriou, J.; Burchell, J.M.; et al. Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor. *J. Immunol.* **2008**, *180*, 4901–4909. [[CrossRef](#)]
277. Azadi, A.; Golchini, A.; Delazar, S.; Kahaki, F.A.; Dehnavi, S.M.; Payandeh, Z.; Eyvazi, S. Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines. *Biol. Proced. Online* **2021**, *23*, 13. [[CrossRef](#)] [[PubMed](#)]
278. Yankelevich, M.; Kondadasula, S.V.; Thakur, A.; Buck, S.; Cheung, N.K.; Lum, L.G. Anti-CD3× anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. *Pediatr. Blood Cancer* **2012**, *59*, 1198–1205. [[CrossRef](#)] [[PubMed](#)]
279. Xu, H.; Cheng, M.; Guo, H.; Chen, Y.; Huse, M.; Cheung, N.K.V. Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody. *Cancer Immunol. Res.* **2015**, *3*, 266–277. [[CrossRef](#)] [[PubMed](#)]
280. Katayose, Y.; Kudo, T.; Suzuki, M.; Shinoda, M.; Saijyo, S.; Sakurai, N.; Saeki, H.; Fukuhara, K.; Imai, K.; Matsuno, S. MUC1-specific targeting immunotherapy with bispecific antibodies: Inhibition of xenografted human bile duct carcinoma growth. *Cancer Res.* **1996**, *56*, 4205–4212.
281. Castenmiller, C.; Keumatio-Doungtsop, B.C.; van Ree, R.; de Jong, E.C.; van Kooyk, Y. Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance. *Front. Immunol.* **2021**, *12*, 643240. [[CrossRef](#)]